

Kaynaklar

- Arbelo E, Protonotarios A, Gimeno JR, et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiomyopathies. *Eur Heart J*. 2023;44(37):3503-3626. [CrossRef]
- Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2015;28(1):1-39.e14. [CrossRef]
- Mitchell C, Rahko PS, Blauwet LA, et al. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. *J Am Soc Echocardiogr*. 2019;32(1):1-64. [CrossRef]
- Lang RM, Badano LP, Tsang W, et al. American Society of Echocardiography; European Association of Echocardiography. EAE/ASE recommendations for image acquisition and display using three-dimensional echocardiography. *J Am Soc Echocardiogr*. 2012;25(1):3-46. [CrossRef]
- Bhave NM, Lang RM. Evaluation of left ventricular structure and function by three-dimensional echocardiography. *Curr Opin Crit Care*. 2013;19(5):387-396. [CrossRef]
- Chahal NS, Lim TK, Jain P, Chambers JC, Kooner JS, Senior R. Population-based reference values for 3D echocardiographic LV volumes and ejection fraction. *JACC Cardiovasc Imaging*. 2012;5(12):1191-1197. [CrossRef]
- Muraru D, Badano LP, Peluso D, et al. Comprehensive analysis of left ventricular geometry and function by three-dimensional echocardiography in healthy adults. *J Am Soc Echocardiogr*. 2013;26(6):618-628. [CrossRef]
- Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. *Eur Heart J*. 2016;37(23):1850-1858. [CrossRef]
- Nagueh SF, Bierig SM, Budoff MJ, et al.; American Society of Echocardiography; American Society of Nuclear Cardiology; Society for Cardiovascular Magnetic Resonance; Society of Cardiovascular Computed Tomography. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: Endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography. *J Am Soc Echocardiogr*. 2011;24(5):473-498. [CrossRef]
- Celebi AS, Yalcin H, Yalcin F. Current cardiac imaging techniques for detection of left ventricular mass. *Cardiovasc Ultrasound*. 2010;8:19. [CrossRef]
- Mor-Avi V, Sugeng L, Weinert L, et al. Fast measurement of left ventricular mass with real-time three-dimensional echocardiography: comparison with magnetic resonance imaging. *Circulation*. 2004;110(13):1814-1818. [CrossRef]
- Captur G, Manisty C, Moon JC. Cardiac MRI evaluation of myocardial disease. *Heart*. 2016;102(18):1429-1435. [CrossRef]
- Galluzzo A, Fiorelli F, Rossi VA, et al. Multimodality Imaging in Sarcomeric Hypertrophic Cardiomyopathy: Get It Right...on Time. *Life (Basel)*. 2023;13(1):171. [CrossRef]
- Tsang TS, Abhayaratna WP, Barnes ME, et al. Prediction of cardiovascular outcomes with left atrial size: is volume superior to area or diameter? *J Am Coll Cardiol*. 2006;47(5):1018-1023. [CrossRef]
- Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2016;29(4):277-314. [CrossRef]
- Venner C, Selton-Suty C, Huttin O, Erpelding ML, Aliot E, Juillière Y. Right ventricular dysfunction in patients with idiopathic dilated cardiomyopathy: Prognostic value and predictive factors. *Arch Cardiovasc Dis*. 2016;109(4):231-241. [CrossRef]
- Tadic M. Multimodality Evaluation of the Right Ventricle: An Updated Review. *Clin Cardiol*. 2015;38(12):770-776. [CrossRef]
- Rudski LG, Lai WW, Afialo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. *J Am Soc Echocardiogr*. 2010;23(7):685-713; quiz 786-788.
- Focardi M, Cameli M, Carbone SF, et al. Traditional and innovative echocardiographic parameters for the analysis of right ventricular performance in comparison with cardiac magnetic resonance. *Eur Heart J Cardiovasc Imaging*. 2015;16(1):47-52. [CrossRef]
- Thiene G, Nava A, Corrado D, Rossi L, Pennelli N. Right ventricular cardiomyopathy and sudden death in young people. *N Engl J Med*. 1988;318(3):129-33. [CrossRef]
- Leitman M, Lysyansky P, Sidenko S, et al. Two-dimensional strain—a novel software for real-time quantitative echocardiographic assessment of myocardial function. *J Am Soc Echocardiogr*. 2004;17(10):1021-1029. [CrossRef]
- Iacoviello M, Citarelli G, Antoncicchi V, et al. Right Ventricular Longitudinal Strain Measures Independently Predict Chronic Heart Failure Mortality. *Echocardiography*. 2016;33(7):992-1000. [CrossRef]
- Portnoy SG, Rudski LG. Echocardiographic evaluation of the right ventricle: a 2014 perspective. *Curr Cardiol Rep*. 2015;17(4):21. [CrossRef]
- McKenna WJ, Maron BJ, Thiene G. Classification, epidemiology, and global burden of cardiomyopathies. *Circ Res*. 2017;121(7):722-730. [CrossRef]
- Parsai C, O'Hanlon R, Prasad SK, Mohiaddin RH. Diagnostic and prognostic value of cardiovascular magnetic resonance in non-ischaemic cardiomyopathies. *J Cardiovasc Magn Reson*. 2012;14(1):54. [CrossRef]
- Pennell DJ. Cardiovascular magnetic resonance. *Circulation*. 2010;121(5):692-705. [CrossRef]
- Armstrong GT, Plana JC, Zhang N, et al. Screening adult survivors of childhood cancer for cardiomyopathy: Comparison of echocardiography and cardiac magnetic resonance imaging. *J Clin Oncol*. 2012;30(23):2876-2884. [CrossRef]
- Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. *J Am Coll Cardiol*. 2003;41(9):1561-1567. [CrossRef]
- Gulati A, Jabbour A, Ismail TF, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. *JAMA*. 2013;309(9):896-908. [CrossRef]
- Pieroni M, Dello Russo A, Marzo F, et al. High prevalence of myocarditis mimicking arrhythmogenic right ventricular cardiomyopathy differential diagnosis by electroanatomic mapping-guided endomyocardial biopsy. *J Am Coll Cardiol*. 2009;53(8):681-689. [CrossRef]
- Rosario KF, Karra R, Amos K, et al. LMNA cardiomyopathy: Important considerations for the heart failure clinician. *J Card Fail*. 2023;29(12):1657-1666. [CrossRef]
- Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, et al. Genetic variants associated with cancer therapy-induced cardiomyopathy. *Circulation*. 2019;140(1):31-41. [CrossRef]
- Ismail TF, Jabbour A, Gulati A, et al. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. *Heart*. 2014;100(23):1851-1858. [CrossRef]
- Flett AS, Hasleton J, Cook C, et al. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. *JACC Cardiovasc Imaging*. 2011;4(2):150-156. [CrossRef]
- Kiaos A, Daskalopoulos GN, Kamperidis V, Ziakas A, Efthimiadis G, Karamitsos TD. Quantitative late gadolinium enhancement cardiac magnetic resonance and sudden death in hypertrophic cardiomyopathy: A meta-analysis. *JACC Cardiovasc Imaging*. 2023;51936-878X(23):00346-00347. [CrossRef]

36. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: Proposed modification of the task force criteria. *Circulation*. 2010;121(13):1533–1541. [\[CrossRef\]](#)
37. Xu Z, Wang J, Cheng W, et al. Incremental significance of myocardial oedema for prognosis in hypertrophic cardiomyopathy. *Eur Heart J Cardiovasc Imaging*. 2023;24(7):876–884. [\[CrossRef\]](#)
38. Scheel PJ, Murray B, Tichnell C, et al. Arrhythmogenic right ventricular cardiomyopathy presenting as clinical myocarditis in women. *Am J Cardiol*. 2021;145:128–134. [\[CrossRef\]](#)
39. Rodgers CT, Robson MD. Cardiovascular magnetic resonance: Physics and terminology. *Prog Cardiovasc Dis*. 2011;54(3):181–190. [\[CrossRef\]](#)
40. Ferreira VM, Piechnik SK, Robson MD, Neubauer S, Karamitsos TD. Myocardial tissue characterization by magnetic resonance imaging: Novel applications of T1 and T2 mapping. *J Thorac Imaging*. 2014;29(3):147–154. [\[CrossRef\]](#)
41. Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. Cardiac T1 mapping and Extracellular Volume (ECV) in clinical practice: A comprehensive review. *J Cardiovasc Magn Reson*. 2016;18(1):89. [\[CrossRef\]](#)
42. Sibley CT, Noureldin RA, Gai N, et al. T1 mapping in cardiomyopathy at cardiac MR: Comparison with endomyocardial biopsy. *Radiology*. 2012;265(3):724–732. [\[CrossRef\]](#)
43. Sado DM, White SK, Piechnik SK, et al. Identification and assessment of Anderson–Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. *Circ Cardiovasc Imaging*. 2013;6(3):392–398. [\[CrossRef\]](#)
44. Martinez-Naharro A, Kotecha T, Norrington K, et al. Native T1 and extracellular volume in transthyretin amyloidosis. *JACC Cardiovasc Imaging*. 2019;12(5):810–819. [\[CrossRef\]](#)
45. Kottam A, Hanneman K, Schenone A, et al. State-of-the-art imaging of infiltrative cardiomyopathies: A scientific statement from the American Heart Association. *Circ Cardiovasc Imaging*. 2023;16(11):e000081. [\[CrossRef\]](#)
46. Ferreira PF, Kilner PJ, McGill LA, et al. In vivo cardiovascular magnetic resonance diffusion tensor imaging shows evidence of abnormal myocardial laminar orientations and mobility in hypertrophic cardiomyopathy. *J Cardiovasc Magn Reson*. 2014;16(1):87. [\[CrossRef\]](#)
47. Augusto JB, Davies RH, Bhuvana AN, et al. Diagnosis and risk stratification in hypertrophic cardiomyopathy using machine learning wall thickness measurement: A comparison with human test-retest performance. *Lancet Digit Health*. 2021;3(1):e20–e28. [\[CrossRef\]](#)
48. Zhang Q, Burrage MK, Lukaschuk E, et al. Toward replacing late gadolinium enhancement with artificial intelligence virtual native enhancement for gadolinium-free cardiovascular magnetic resonance tissue characterization in hypertrophic cardiomyopathy. *Circulation*. 2021;144(8):589–599. [\[CrossRef\]](#)
49. Rankin K, Thampinathan B, Thavendiranathan P. Imaging-specific cardiomyopathies: A practical guide. *Heart Fail Clin*. 2019;15(2):275–295. [\[CrossRef\]](#)
50. Beanlands RS, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron emission tomography imaging–assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: A randomized, controlled trial (PARR-2). *J Am Coll Cardiol*. 2007;50(20):2002–2012. [\[CrossRef\]](#)
51. Caobelli F, Bengel FM. Ischaemic vs non-ischaemic dilated cardiomyopathy: The value of nuclear cardiology techniques. *J Nucl Cardiol*. 2015;22(5):971–974. [\[CrossRef\]](#)
52. Bravo PE, Di Carli MF, Dorbala S. Role of PET to evaluate coronary microvascular dysfunction in non-ischemic cardiomyopathy. *Heart Fail Rev*. 2017;22(4):455–464. [\[CrossRef\]](#)
53. Neglia D, Michelassi C, Trivieri MG, et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. *Circulation*. 2002;105(2):186–193. [\[CrossRef\]](#)
54. Majumdar MD, Murthy VL, Shah RV, et al. Quantification of coronary flow reserve in patients with ischaemic and non-ischaemic cardiomyopathy and its association with clinical outcomes. *Eur Heart J Cardiovasc Imaging*. 2015;16(8):900–909. [\[CrossRef\]](#)
55. Timmer SA, Knaepen P. Coronary microvascular function, myocardial metabolism, and energetics in hypertrophic cardiomyopathy: Insights from positron emission tomography. *Eur Heart J Cardiovasc Imaging*. 2013;14(2):95–101. [\[CrossRef\]](#)
56. Werner RA, Chen X, Hirano M, et al. SPECT vs. PET in cardiac innervation imaging: Clash of the titans. *Clin Transl Imaging*. 2018;6(4):293–303. [\[CrossRef\]](#)
57. Fallavollita JA, Heavey BM, Luisi AJ Jr, et al. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. *J Am Coll Cardiol*. 2014;63(2):141–149. [\[CrossRef\]](#)
58. Narula J, Gerson M, Thomas GS, Cerqueira MD, Jacobson AF. ^{123I}-MIBG imaging for prediction of mortality and potentially fatal events in heart failure: The ADMIRE-HFX study. *J Nucl Med*. 2015;56(7):1011–1018. [\[CrossRef\]](#)
59. Travin MI. Current clinical applications and next steps for cardiac innervation imaging. *Curr Cardiol Rep*. 2017;19(1):1. [\[CrossRef\]](#)
60. Dorbala S, Shaw LJ. Molecular phenotyping of infiltrative cardiomyopathies: The future. *J Nucl Cardiol*. 2019;26(1):154–157. [\[CrossRef\]](#)
61. Falk RH. Diagnosis and management of the cardiac amyloidoses. *Circulation*. 2005;112(13):2047–2060. [\[CrossRef\]](#)
62. Erba PA, Pizzi MN, Roque A, Slart RHJA. Nuclear imaging in the new ESC Guidelines: The age of maturity. *Eur J Nucl Med Mol Imaging*. 2024;51(4):938–941. [\[CrossRef\]](#)
63. Slart RHJA, Chen W, Tubben A, et al. Emerging role of scintigraphy using bone-seeking tracers for diagnosis of cardiac amyloidosis: AJR expert panel narrative review. *AJR Am J Roentgenol*. 2024;222(1):e2329347. [\[CrossRef\]](#)
64. Dorbala S, Cuddy S, Falk RH. How to image cardiac amyloidosis: A practical approach. *JACC Cardiovasc Imaging*. 2020;13(6):1368–1383. [\[CrossRef\]](#)
65. Rapezzi C, Gagliardi C, Milandri A. Analogies and disparities among scintigraphic bone tracers in the diagnosis of cardiac and non-cardiac ATTR amyloidosis. *J Nucl Cardiol*. 2019;26(5):1638–1641. [\[CrossRef\]](#)
66. Stats MA, Stone JR. Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis. *Cardiovasc Pathol*. 2016;25(5):413–417. [\[CrossRef\]](#)
67. Pilebro B, Suhr OB, Näslund U, Westermark P, Lindqvist P, Sundström T. (99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis. *Ups J Med Sci*. 2016;121(1):17–24. [\[CrossRef\]](#)
68. Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2–Evidence base and standardized methods of imaging. *Circ Cardiovasc Imaging*. 2021;14(7):e000029. [\[CrossRef\]](#)
69. Özdemir E, Coşkun N, Durmuş-Altun G, et al. Kardiyak transtiretin tip amiloidoz değerlendirilmesinde sintigrafik görüntüleme kılavuzu. *Nucl Med Semin*. 2024;10(1):90–103. [\[CrossRef\]](#)
70. Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. *J Am Coll Cardiol*. 2005;46(6):1076–1084. [\[CrossRef\]](#)
71. Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. *Circ Cardiovasc Imaging*. 2013;6(2):195–201. [\[CrossRef\]](#)
72. Castano A, Haq M, Narotsky DL, et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: Predicting survival for patients with ATTR cardiac amyloidosis. *JAMA Cardiol*. 2016;1(8):880–889. [\[CrossRef\]](#)
73. Dorbala S, Park MA, Cuddy S, et al. Absolute quantitation of cardiac 99mTc-pyrophosphate using Cadmium–Zinc–Telluride–based SPECT/CT. *J Nucl Med*. 2021;62(5):716–722. [\[CrossRef\]](#)
74. Gerber J, Miller EJ. Optimal interpretation of Tc99m PYP in 2020: Avoiding the million-dollar mistake. *J Nucl Cardiol*. 2021;28(2):503–506. [\[CrossRef\]](#)

75. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. *Circulation*. 2016;133(24):2404-2412. [CrossRef]
76. Porcari A, Fontana M, Canepa M, et al. Clinical and prognostic implications of right ventricular uptake on bone scintigraphy in transthyretin amyloid cardiomyopathy. *Circulation*. 2024;149(15):1157-1168. [CrossRef]
77. Musumeci MB, Cappelli F, Russo D, et al. Low sensitivity of bone scintigraphy in detecting Phe64Leu mutation-related transthyretin cardiac amyloidosis. *JACC Cardiovasc Imaging*. 2020;13(6):1314-1321. [CrossRef]
78. Coşkun N, Özdemir E, Canbaz-Tosun F. Kardiyak amiloidozda radyonükleit kardiyak görüntüleme. *Nucl Med Semin*. 2024;10(1):19-27. [CrossRef]
79. Dorbala S, Vangala D, Bruyere J Jr, et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. *JACC Heart Fail*. 2014;2(4):358-367. [CrossRef]
80. Çağlayan F. I-123 MIBG ve analog PET radyofarmasotikleri ile kardiyak innervasyon görüntüleme. In: Kibar M. *Nükleer Tıp ve Moleküler Görüntüleme*. Ankara: Akademisyen Yayınevi; 2023:699-710.
81. Jonker DL, Hazenberg BPC, Nienhuis HLA, Slart RHJA, Glandemans AWJM, Noordzij W. Imaging cardiac innervation in hereditary transthyretin (ATTRm) amyloidosis: A marker for neuropathy or cardiomyopathy in case of heart failure? *J Nucl Cardiol*. 2020;27(5):1774-1784. [CrossRef]
82. Kim YJ, Ha S, Kim YI. Cardiac amyloidosis imaging with amyloid positron emission tomography: A systematic review and meta-analysis. *J Nucl Cardiol*. 2020;27(1):123-132. [CrossRef]
83. Genovesi D, Vergaro G, Giorgetti A, et al. [18F]-florbetaben PET/CT for differential diagnosis among cardiac immunoglobulin light chain, transthyretin amyloidosis, and mimicking conditions. *JACC Cardiovasc Imaging*. 2021;14(1):246-255. [CrossRef]
84. Birnie DH, Kandolin R, Nery PB, Kupari M. Cardiac manifestations of sarcoidosis: Diagnosis and management. *Eur Heart J*. 2017;38(35):2663-2670. [CrossRef]
85. Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: A systematic review and metaanalysis including the Ontario experience. *J Nucl Med*. 2012;53(2):241-248. [CrossRef]
86. Saraste A, Knuuti J. PET imaging in heart failure: the role of new tracers. *Heart Fail Rev*. 2017;22(4):501-511. [CrossRef]
87. Ohira H, Tsujino I, Ishimaru S, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. *Eur J Nucl Med Mol Imaging*. 2008;35(5):933-941. [CrossRef]
88. Hulthen E, Aslam S, Osborne M, Abbasi S, Bittencourt MS, Blankstein R. Cardiac sarcoidosis-State of the art review. *Cardiovasc Diagn Ther*. 2016;6(1):50-63.
89. Ahmadian A, Pawar S, Govender P, Berman J, Ruberg FL, Miller EJ. The response of FDG uptake to immunosuppressive treatment on FDG PET/CT imaging for cardiac sarcoidosis. *J Nucl Cardiol*. 2017;24(2):413-424. [CrossRef]
90. Şen F, Demir H, Durmuş-Altun G, Özdemir E, Özdemir S, Canbaz-Tosun F. Kardiyak sarkoidozda F-18 FDG PET/BT ile enflamasyon görüntüleme kılavuzu. *Nucl Med Semin*. 2020;6:211-219. [CrossRef]
91. Tang R, Wang JT, Wang L, et al. Impact of patient preparation on the diagnostic performance of 18F-FDG PET in cardiac sarcoidosis: A systematic review and meta-analysis. *Clin Nucl Med*. 2016;41(7):e327-e339. [CrossRef]
92. Osborne MT, Hulthen EA, Murthy VL, et al. Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation. *J Nucl Cardiol*. 2017;24(1):86-99. [CrossRef]
93. Lapa C, Reiter T, Kircher M, et al. Somatostatin receptor based PET/CT in patients with the suspicion of cardiac sarcoidosis: An initial comparison to cardiac MRI. *Oncotarget*. 2016;7(47):77807-77814. [CrossRef]
94. Norikane T, Yamamoto Y, Maeda Y, Noma T, Nishiyama Y. 18F-FLT PET imaging in a patient with sarcoidosis with cardiac involvement. *Clin Nucl Med*. 2015;40(5):433-434. [CrossRef]
95. Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. *J Am Coll Cardiol*. 2014;63(4):329-336. [CrossRef]
96. Syed FF, Schaff HV, Oh JK. Constrictive pericarditis--a curable diastolic heart failure. *Nat Rev Cardiol*. 2014;11(9):530-544. Erratum in: *Nat Rev Cardiol*. 2015;12(12):682. [CrossRef]
97. Bertog SC, Thambidorai SK, Parakh K, et al. Constrictive pericarditis: etiology and cause-specific survival after pericardiectomy. *J Am Coll Cardiol*. 2004;43(8):1445-1452. [CrossRef]
98. Szabó G, Schmack B, Bulut C, et al. Constrictive pericarditis: risks, aetiologies and outcomes after total pericardiectomy: 24 years of experience. *Eur J Cardiothorac Surg*. 2013;44(6):1023-1028; discussion 1028. [CrossRef]
99. Mogensen J, van Tintelen JP, Fokstuen S, et al. The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and members of the European Society of Human Genetics. *Eur Heart J*. 2015;36(22):1367-1370. [CrossRef]
100. Gallego-Delgado M, Delgado JF, Brossa-Loidi V, et al. Idiopathic Restrictive Cardiomyopathy Is Primarily a Genetic Disease. *J Am Coll Cardiol*. 2016;67(25):3021-3023. [CrossRef]
101. Elliot P, Haugaa KH, Caso P, Cikes M. Restrictive cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy. In: Lancellotti P, Zamorano JL, Habib G, Badano L, eds. *The EACVI Textbook of Echocardiography*. Oxford: Oxford University Press; 2016:386-393. [CrossRef]
102. Adler Y, Charron P, Imazio M, et al.; ESC Scientific Document Group. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J*. 2015;36(42):2921-2964. [CrossRef]
103. Arbelo E, Protonotarios A, Gimeno JR, et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiomyopathies. *Eur Heart J*. 2023;44(37):3503-3626. [CrossRef]
104. Miranda WR, Oh JK. Constrictive Pericarditis: A Practical Clinical Approach. *Prog Cardiovasc Dis*. 2017;59(4):369-379. [CrossRef]
105. Welch TD, Ling LH, Espinosa RE, et al. Echocardiographic diagnosis of constrictive pericarditis: Mayo Clinic criteria. *Circ Cardiovasc Imaging*. 2014;7(3):526-534. [CrossRef]
106. Talreja DR, Nishimura RA, Oh JK, Holmes DR. Constrictive pericarditis in the modern era: novel criteria for diagnosis in the cardiac catheterization laboratory. *J Am Coll Cardiol*. 2008;51(3):315-319. [CrossRef]
107. Ling LH, Schaff HV, dal-Bianco J. Detection of constrictive pericarditis: A single-centre experience of 523 surgically confirmed cases [abstract]. *J Am Coll Cardiol*. 2009;53:A176.
108. Klein AL, Abbara S, Agler DA, et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. *J Am Soc Echocardiogr*. 2013;26(9):965-1012.e15. [CrossRef]
109. Cosyns B, Plein S, Nihoyanopoulos P, et al.; European Association of Cardiovascular Imaging (EACVI); European Society of Cardiology Working Group (ESC WG) on Myocardial and Pericardial diseases. European Association of Cardiovascular Imaging (EACVI) position paper: Multimodality imaging in pericardial disease. *Eur Heart J Cardiovasc Imaging*. 2015;16(1):12-31. [CrossRef]
110. Paelinck B, Lazarević A, Fajardo PG. Pericardial disease. In: Lancellotti P, Zamorano JL, Habib G, Badano L, eds. *The EACVI Textbook of Echocardiography*. Oxford: Oxford University Press; 2016:420-428. [CrossRef]
111. Lloyd JW, Anavekar NS, Oh JK, Miranda WR. Multimodality Imaging in Differentiating Constrictive Pericarditis From Restrictive Cardiomyopathy: A Comprehensive Overview for Clinicians and Imagers. *J Am Soc Echocardiogr*. 2023;36(12):1254-1265. [CrossRef]

112. Nagueh SF, Sun H, Kopelen HA, Middleton KJ, Khoury DS. Hemodynamic determinants of the mitral annulus diastolic velocities by tissue Doppler. *J Am Coll Cardiol*. 2001;37(1):278-285. [\[CrossRef\]](#)
113. Oh JK. Echocardiography as a noninvasive Swan-Ganz catheter. *Circulation*. 2005;111(24):3192-3194. Erratum in: *Circulation*. 2005;112(5):e75. [\[CrossRef\]](#)
114. Oh JK, Appleton CP, Hatle LK, Nishimura RA, Seward JB, Tajik AJ. The noninvasive assessment of left ventricular diastolic function with two-dimensional and Doppler echocardiography. *J Am Soc Echocardiogr*. 1997;10(3):246-270. [\[CrossRef\]](#)
115. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part 1. *Circulation*. 2002;105(11):1387-1393.
116. Smiseth OA, Galderisi M, Oh JK. Left ventricle: diastolic function. *The EACVI Textbook of Echocardiography*. Oxford: Oxford University Press;147-161.
117. Yang JH, Miranda WR, Nishimura RA, Greason KL, Schaff HV, Oh JK. Prognostic importance of mitral e' velocity in constrictive pericarditis. *Eur Heart J Cardiovasc Imaging*. 2021;22(3):357-364. [\[CrossRef\]](#)
118. Oh JK, Hatle LK, Seward JB, et al. Diagnostic role of Doppler echocardiography in constrictive pericarditis. *J Am Coll Cardiol*. 1994;23(1):154-162. [\[CrossRef\]](#)
119. Smiseth OA, Remme EW, Opdahl A, Aakhus S, Skulstad H. Heart failure with normal left ventricular ejection fraction: basic principles and clinical diagnostics. In: Bartunek J, Vanderheyden M, eds. *Translational Approach to Heart Failure*. New York: Springer;2013:25-62. [\[CrossRef\]](#)
120. Ommen SR, Nishimura RA, Appleton CP, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study. *Circulation*. 2000;102(15):1788-1794. [\[CrossRef\]](#)
121. Smiseth OA, Thompson CR, Lohavanichbutr K, et al. The pulmonary venous systolic flow pulse--its origin and relationship to left atrial pressure. *J Am Coll Cardiol*. 1999;34(3):802-809. [\[CrossRef\]](#)
122. Asher CR, Klein AL. Diastolic heart failure: restrictive cardiomyopathy, constrictive pericarditis, and cardiac tamponade: clinical and echocardiographic evaluation. *Cardiol Rev*. 2002;10(4):218-229. [\[CrossRef\]](#)
123. Sengupta PP, Krishnamoorthy VK, Abhayaratna WP, et al. Disparate patterns of left ventricular mechanics differentiate constrictive pericarditis from restrictive cardiomyopathy. *JACC Cardiovasc Imaging*. 2008;1(1):29-38. [\[CrossRef\]](#)
124. Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. *N Engl J Med*. 1997;336(4):267-276. [\[CrossRef\]](#)
125. Mahmoud A, Bansal M, Sengupta PP. New Cardiac Imaging Algorithms to Diagnose Constrictive Pericarditis Versus Restrictive Cardiomyopathy. *Curr Cardiol Rep*. 2017;19(5):43. [\[CrossRef\]](#)
126. Talreja DR, Edwards WD, Danielson GK, et al. Constrictive pericarditis in 26 patients with histologically normal pericardial thickness. *Circulation*. 2003;108(15):1852-1857. [\[CrossRef\]](#)
127. Nazarian S, Hansford R, Rahsepar AA, et al. Safety of Magnetic Resonance Imaging in Patients with Cardiac Devices. *N Engl J Med*. 2017;377(26):2555-2564. [\[CrossRef\]](#)
128. Russo RJ, Costa HS, Silva PD, et al. Assessing the Risks Associated with MRI in Patients with a Pacemaker or Defibrillator. *N Engl J Med*. 2017;376(8):755-764.
129. Cheng H, Zhao S, Jiang S, et al. The relative atrial volume ratio and late gadolinium enhancement provide additive information to differentiate constrictive pericarditis from restrictive cardiomyopathy. *J Cardiovasc Magn Reson*. 2011;13(1):15. [\[CrossRef\]](#)
130. Masui T, Finck S, Higgins CB. Constrictive pericarditis and restrictive cardiomyopathy: evaluation with MR imaging. *Radiology*. 1992;182(2):369-373. [\[CrossRef\]](#)
131. Alter P, Figiel JH, Rupp TP, Bachmann GF, Maisch B, Rominger MB. MR, CT, and PET imaging in pericardial disease. *Heart Fail Rev*. 2013;18(3):289-306. [\[CrossRef\]](#)
132. Gahide G, Granier M, Frapier JM. Effusive constrictive pericarditis: functional and anatomical magnetic resonance findings. *Eur Heart J*. 2009;30(11):1371. [\[CrossRef\]](#)
133. Bogabathina H, Biederman RW. Lack of slippage by cardiovascular magnetic resonance imaging is sine qua non for constrictive pericarditis. *Circulation*. 2011;123(16):e418-e419. [\[CrossRef\]](#)
134. Kojima S, Yamada N, Goto Y. Diagnosis of constrictive pericarditis by tagged cine magnetic resonance imaging. *N Engl J Med*. 1999;341(5):373-374. [\[CrossRef\]](#)
135. Amaki M, Savino J, Ain DL, et al. Diagnostic concordance of echocardiography and cardiac magnetic resonance-based tissue tracking for differentiating constrictive pericarditis from restrictive cardiomyopathy. *Circ Cardiovasc Imaging*. 2014;7(5):819-827. [\[CrossRef\]](#)
136. Aquaro GD, Barison A, Cagnolo A, Todiere G, Lombardi M, Emdin M. Role of tissue characterization by Cardiac Magnetic Resonance in the diagnosis of constrictive pericarditis. *Int J Cardiovasc Imaging*. 2015;31(5):1021-1031. [\[CrossRef\]](#)
137. Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. *JACC Cardiovasc Imaging*. 2010;3(2):155-164. [\[CrossRef\]](#)
138. Francone M, Dymarkowski S, Kalantzi M, Rademakers FE, Bogaert J. Assessment of ventricular coupling with real-time cine MRI and its value to differentiate constrictive pericarditis from restrictive cardiomyopathy. *Eur Radiol*. 2006;16(4):944-951. [\[CrossRef\]](#)
139. Anavekar NS, Wong BF, Foley TA, et al. Index of biventricular interdependence calculated using cardiac MRI: a proof of concept study in patients with and without constrictive pericarditis. *Int J Cardiovasc Imaging*. 2013;29(2):363-369. [\[CrossRef\]](#)
140. Diaz Soto JC, Mauermann WJ, Lahr BD, Schaff HV, Luis SA, Smith MM. MELD and MELD XI Scores as Predictors of Mortality After Pericardiectomy for Constrictive Pericarditis. *Mayo Clin Proc*. 2021;96(3):619-635. [\[CrossRef\]](#)
141. Bogaert J, Dresselaers T, Imazio M, et al. Noninvasive assessment of congestive hepatopathy in patients with constrictive pericardial physiology using MR relaxometry. *Int J Cardiol*. 2021;338:265-273. [\[CrossRef\]](#)
142. Chetrit M, Xu B, Kwon DH, Ramchand J, et al. Imaging-Guided Therapies for Pericardial Diseases. *JACC Cardiovasc Imaging*. 2020;13(6):1422-1437. Erratum in: *JACC Cardiovasc Imaging*. 2021;14(9):1884. [\[CrossRef\]](#)
143. Feng D, Glockner J, Kim K, et al. Cardiac magnetic resonance imaging pericardial late gadolinium enhancement and elevated inflammatory markers can predict the reversibility of constrictive pericarditis after antiinflammatory medical therapy: a pilot study. *Circulation*. 2011;124(17):1830-1837. [\[CrossRef\]](#)
144. Chambers DC, Cherkh WS, Goldfarb SB, et al. The international thoracic organ transplant registry of the international society for heart and lung transplantation: Thirty-fifth adult lung and heart-lung transplant report-2018; Focus theme: Multiorgan transplantation. *J Heart Lung Transplant*. 2018;37(10):1169-1183. [\[CrossRef\]](#)
145. Mitropoulou P, Georgiopoulos G, Figliozzi S, Klettas D, Nicoli F, Masci PG. Multi-modality imaging in dilated cardiomyopathy: With a focus on the role of cardiac magnetic resonance. *Front Cardiovasc Med*. 2020;7:97. [\[CrossRef\]](#)
146. van Waning JJ, Caliskan K, Michels M, et al. Cardiac phenotypes, genetics, and risks in familial noncompaction cardiomyopathy. *J Am Coll Cardiol*. 2019;73(13):1601-1611. [\[CrossRef\]](#)
147. Pettersen MD, Du W, Skeens ME, Humes RA. Regression equations for calculation of z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: An echocardiographic study. *J Am Soc Echocardiogr*. 2008;21(8):922-934. [\[CrossRef\]](#)
148. Millar LM, Fanton Z, Finocchiaro G, et al. Differentiation between athlete's heart and dilated cardiomyopathy in athletic individuals. *Heart*. 2020;106(14):1059-1065. [\[CrossRef\]](#)
149. Halliday BP. State of the art: multimodality imaging in dilated cardiomyopathy. *Heart*. 2022;108(23):1910-1917. [\[CrossRef\]](#)
150. Caballero L, Kou S, Dulgheru R, et al. Echocardiographic reference ranges for normal cardiac Doppler data: Results from the NORRE Study. *Eur Heart J Cardiovasc Imaging*. 2015;16(9):1031-1041. [\[CrossRef\]](#)

151. Verdonschot JAJ, Merken JJ, Rocca HPBL, et al. Value of speckle tracking-based deformation analysis in screening relatives of patients with asymptomatic dilated cardiomyopathy. *JACC Cardiovasc Imaging*. 2020;13(2 Pt 2):549-558. [CrossRef]
152. Lakdawala NK, Thune JJ, Colan SD, et al. Subtle abnormalities in contractile function are an early manifestation of sarcomere mutations in dilated cardiomyopathy. *Circ Cardiovasc Genet*. 2012;5(5):503-510. [CrossRef]
153. Gulati A, Ismail TF, Jabbour A, et al. The prevalence and prognostic significance of right ventricular systolic dysfunction in nonischemic dilated cardiomyopathy. *Circulation* 2013;128:1623-33. [CrossRef]
154. Mathew T, Williams L, Navaratnam G, et al. Diagnosis and assessment of dilated cardiomyopathy: A guideline protocol from the British Society of Echocardiography. *Echo Res Pract*. 2017;4(2):G1-G13. [CrossRef]
155. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail*. 2022;24(1):4-131.
156. Stankovic I, Prinz C, Ciarka A, et al. Relationship of visually assessed apical rocking and septal flash to response and long-term survival following cardiac resynchronization therapy (PREDICT-CRT). *Eur Heart J Cardiovasc Imaging*. 2016;17(3):262-269. [CrossRef]
157. Parsai C, Baltabaeva A, Anderson L, Chaparro M, Bijmens B, Sutherland GR. Low-dose dobutamine stress echo to quantify the degree of remodelling after cardiac resynchronization therapy. *Eur Heart J*. 2009;30(8):950-958. [CrossRef]
158. Galli E, Leclercq C, Fournet M, et al. Value of myocardial work estimation in the prediction of response to cardiac resynchronization therapy. *J Am Soc Echocardiogr*. 2018;31(2):220-230. [CrossRef]
159. Waddingham PH, Bhattacharyya S, Zalen JV, Lloyd G. Contractile reserve as a predictor of prognosis in patients with non-ischaemic systolic heart failure and dilated cardiomyopathy: A systematic review and meta-analysis. *Echo Res Pract*. 2018;5(1):1-9. [CrossRef]
160. Rossi A, Dini FL, Faggiano P, et al. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. *Heart*. 2011;97(20):1675-1680. [CrossRef]
161. Adamo M, Fiorelli F, Melica B, et al. COAPT-like profile predicts long-term outcomes in patients with secondary mitral regurgitation undergoing mitralclip implantation. *JACC Cardiovasc Interv*. 2021;14(1):15-25. [CrossRef]
162. Kukucka M, Stepanenko A, Potapov E, et al. Right-to-left ventricular end-diastolic diameter ratio and prediction of right ventricular failure with continuous-flow left ventricular assist devices. *J Heart Lung Transplant*. 2011;30(1):64-69. [CrossRef]
163. Assomull RG, Shakespeare C, Kalra PR, et al. Role of cardiovascular magnetic resonance as a gatekeeper to invasive coronary angiography in patients presenting with heart failure of unknown etiology. *Circulation*. 2011;124(12):1351-1360. [CrossRef]
164. Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur Heart J*. 2013;34(33):2636-2648. [CrossRef]
165. GhadriJR, Wittstein IS, Prasad A, et al. International expert consensus document on takotsubo syndrome (part II): diagnostic workup, outcome, and management. *Eur Heart J*. 2018;39(22):2047-2062. [CrossRef]
166. Levin B, Baughman RP, Sweiss NJ. Detection of early phenotype cardiac sarcoidosis by cardiovascular magnetic resonance. *Curr Opin Pulm Med*. 2021;27(5):478-483. [CrossRef]
167. Wood JC, Otto-Duessel M, Aguilar M, et al. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. *Circulation*. 2005;112(4):535-543. [CrossRef]
168. Pepe A, Meloni A, Rossi G, et al. Prediction of cardiac complications for thalassemia major in the widespread cardiac magnetic resonance era: A prospective multicentre study by a multi-parametric approach. *Eur Heart J Cardiovasc Imaging*. 2018;19(3):299-309. [CrossRef]
169. Tayal U, Newsome S, Buchan R, et al. Phenotype and clinical outcomes of titin cardiomyopathy. *J Am Coll Cardiol*. 2017;70(18):2264-2274. [CrossRef]
170. Augusto JB, Eiros R, Nakou E, et al. Dilated cardiomyopathy and arrhythmogenic left ventricular cardiomyopathy: A comprehensive genotype-imaging phenotype study. *Eur Heart J Cardiovasc Imaging*. 2020;21(3):326-336. [CrossRef]
171. Corrado D, Basso C, Thiene G, et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: A multicenter study. *J Am Coll Cardiol*. 1997;30(6):1512-1520. [CrossRef]
172. Arbustini E, Di Toro A, Giuliani L, Favalli V, Narula N, Grasso M. Cardiac phenotypes in hereditary muscle disorders: JACC state-of-the-art review. *J Am Coll Cardiol*. 2018;72(20):2485-2506. [CrossRef]
173. Alba AC, Gaztañaga J, Foroutan F, et al. Prognostic value of late gadolinium enhancement for the prediction of cardiovascular outcomes in dilated cardiomyopathy: An international, multi-institutional study of the MINICOR group. *Circ Cardiovasc Imaging*. 2020;13(4):e010105. [CrossRef]
174. Masci PG, Schuurman R, Andrea B, et al. Myocardial fibrosis as a key determinant of left ventricular remodeling in idiopathic dilated cardiomyopathy: A contrast-enhanced cardiovascular magnetic study. *Circ Cardiovasc Imaging*. 2013;6(5):790-799. [CrossRef]
175. Leyva F, Taylor RJ, Foley PW, et al. Left ventricular midwall fibrosis as a predictor of mortality and morbidity after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy. *J Am Coll Cardiol*. 2012;60(17):1659-1667. [CrossRef]
176. Rapezzi C, Arbustini E, Caforio AL, et al. Diagnostic work-up in cardiomyopathies: Bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. *Eur Heart J*. 2013;34(19):1448-1458. [CrossRef]
177. Bax JJ, Kraft O, Buxton AE, et al. 123 I-mIBG scintigraphy to predict inducibility of ventricular arrhythmias on cardiac electrophysiology testing: a prospective multicenter pilot study. *Circ Cardiovasc Imaging*. 2008;1(2):131-140. [CrossRef]
178. Gimelli A, Liga R, Avogliero F, Coceani M, Marzullo P. Relationships between left ventricular sympathetic innervation and diastolic dysfunction: The role of myocardial innervation/perfusion mismatch. *J Nucl Cardiol*. 2018;25(4):1101-1109. [CrossRef]
179. Caobelli F, Cabrero JB, Galea N, et al. Cardiovascular magnetic resonance (CMR) and positron emission tomography (PET) imaging in the diagnosis and follow-up of patients with acute myocarditis and chronic inflammatory cardiomyopathy: A review paper with practical recommendations on behalf of the European Society of Cardiovascular Radiology (ESCR). *Int J Cardiovasc Imaging*. 2023;39(11):2221-2235. [CrossRef]
180. Tsampasian V, Cameron D, Sobhan R, Bazoukis G, Vassiliou VS. Phosphorus magnetic resonance spectroscopy (³¹P MRS) and cardiovascular disease: The importance of energy. *Medicina (Kaunas)*. 2023;59(1):174. [CrossRef]
181. Spath NB, Singh T, Papanastasiou G, et al. Manganese-enhanced magnetic resonance imaging in dilated cardiomyopathy and hypertrophic cardiomyopathy. *Eur Heart J Cardiovasc Imaging*. 2021;22:1463-1472. [CrossRef]
182. Donal E, Delgado V, Bucciarelli-Ducci C, et al. Multimodality imaging in the diagnosis, risk stratification, and management of patients with dilated cardiomyopathies: an expert consensus document from the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*. 2019;20(10):1075-1093. [CrossRef]
183. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2020;142(25):e558-e631. Erratum in: *Circulation*. 2020;142(25):e633. [CrossRef]

184. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2015;65(12):1249-1254. [CrossRef]
185. Neubauer S, Kolm P, Ho CY, Kwong RY, et al.; HCMR Investigators. Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry. *J Am Coll Cardiol*. 2019;74(19):2333-2345. [CrossRef]
186. Borrelli F, Losi MA, Canciello G, et al. Sarcomeric versus Non-Sarcomeric HCM. *Cardiogenetics*. 2023;13(12):92-105. [CrossRef]
187. Erdmann J, Daehmlow S, Wischke S, et al. Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy. *Clin Genet*. 2003;64(4):339-349. [CrossRef]
188. Kaski JP, Syrris P, Esteban MT, et al. Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy. *Circ Cardiovasc Genet*. 2009;2(5):436-441. [CrossRef]
189. Maron BJ, Desai MY, Nishimura RA, et al. Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2022;79(4):372-389. [CrossRef]
190. Mitchell CC, Frye C, Jankowski M, et al. A Practical Approach to Echocardiographic Imaging in Patients With Hypertrophic Cardiomyopathy. *J Am Soc Echocardiogr*. 2023;36(9):913-932. [CrossRef]
191. Robinson S, Rana B, Oxborough D, et al. A practical guideline for performing a comprehensive transthoracic echocardiogram in adults: the British Society of Echocardiography minimum dataset. *Echo Res Pract*. 2020;7(4):G59-G93. [CrossRef]
192. Maron BJ, Rowin EJ, Maron MS, Braunwald E. Nonobstructive Hypertrophic Cardiomyopathy Out of the Shadows: Known from the Beginning but Largely Ignored ... Until Now. *Am J Med*. 2017;130(2):119-123. [CrossRef]
193. Maron MS, Olivetto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. *N Engl J Med*. 2003;348(4):295-303. [CrossRef]
194. Boughner DR, Schuld RL, Persaud JA. Hypertrophic obstructive cardiomyopathy. Assessment by echocardiographic and Doppler ultrasound techniques. *Br Heart J*. 1975;37(9):917-923. [CrossRef]
195. Nagueh SF, Phelan D, Abraham T, et al. Recommendations for Multimodality Cardiovascular Imaging of Patients with Hypertrophic Cardiomyopathy: An Update from the American Society of Echocardiography, in Collaboration with the American Society of Nuclear Cardiology, the Society for Cardiovascular Magnetic Resonance, and the Society of Cardiovascular Computed Tomography. *J Am Soc Echocardiogr*. 2022;35(6):533-569. [CrossRef]
196. Ayoub C, Geske JB, Larsen CM, Scott CG, Klarich KW, Pellikka PA. Comparison of Valsalva Maneuver, Amyl Nitrite, and Exercise Echocardiography to Demonstrate Latent Left Ventricular Outflow Obstruction in Hypertrophic Cardiomyopathy. *Am J Cardiol*. 2017;120(12):2265-2271. [CrossRef]
197. Sherrid MV, Balaram S, Kim B, Axel L, Swistel DG. The Mitral Valve in Obstructive Hypertrophic Cardiomyopathy: A Test in Context. *J Am Coll Cardiol*. 2016;67(15):1846-1858. [CrossRef]
198. Hong JH, Schaff HV, Nishimura RA, et al. Mitral Regurgitation in Patients With Hypertrophic Obstructive Cardiomyopathy: Implications for Concomitant Valve Procedures. *J Am Coll Cardiol*. 2016;68(14):1497-1504. [CrossRef]
199. Groarke JD, Galazka PZ, Cirino AL, et al. Intrinsic mitral valve alterations in hypertrophic cardiomyopathy sarcomere mutation carriers. *Eur Heart J Cardiovasc Imaging*. 2018;19(10):1109-1116. [CrossRef]
200. Vahanian A, Beyersdorf F, Praz F, et al.; ESC/EACTS Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J*. 2022;43(7):561-632. Erratum in: *Eur Heart J*. 2022. [CrossRef]
201. Harrigan CJ, Appelbaum E, Maron BJ, et al. Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. *Am J Cardiol*. 2008;101(5):668-673. [CrossRef]
202. Kwon DH, Smedira NG, Thamilarasan M, Lytle BW, Lever H, Desai MY. Characteristics and surgical outcomes of symptomatic patients with hypertrophic cardiomyopathy with abnormal papillary muscle morphology undergoing papillary muscle reorientation. *J Thorac Cardiovasc Surg*. 2010;140(2):317-324. [CrossRef]
203. Kwon DH, Setser RM, Thamilarasan M, et al. Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. *Heart*. 2008;94(10):1295-1301. [CrossRef]
204. Hahn RT, Abraham T, Adams MS, et al. Guidelines for performing a comprehensive transesophageal echocardiographic examination: recommendations from the American Society of Echocardiography and the Society of Cardiovascular Anesthesiologists. *J Am Soc Echocardiogr*. 2013;26(9):921-964. [CrossRef]
205. Lee DZJ, Montazeri M, Bataiosu R, et al. Clinical Characteristics and Prognostic Importance of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy. *JACC Cardiovasc Imaging*. 2022;15(10):1696-1711. [CrossRef]
206. Maron MS, Finley JJ, Bos JM, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. *Circulation*. 2008;118(15):1541-1549. [CrossRef]
207. Sherrid MV, Bernard S, Tripathi N, et al. Apical Aneurysms and Mid-Left Ventricular Obstruction in Hypertrophic Cardiomyopathy. *JACC Cardiovasc Imaging*. 2023;16(5):591-605. [CrossRef]
208. Rowin EJ, Maron BJ, Haas TS, et al. Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management. *J Am Coll Cardiol*. 2017;69(7):761-773. Erratum in: *J Am Coll Cardiol*. 2017;69(12):1652. [CrossRef]
209. Yang K, Song YY, Chen XY, et al. Apical hypertrophic cardiomyopathy with left ventricular apical aneurysm: prevalence, cardiac magnetic resonance characteristics, and prognosis. *Eur Heart J Cardiovasc Imaging*. 2020;21(12):1341-1350. [CrossRef]
210. Thaman R, Gimeno JR, Murphy RT, et al. Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. *Heart*. 2005;91(7):920-925. [CrossRef]
211. McMahon CJ, Nagueh SF, Pignatelli RH, et al. Characterization of left ventricular diastolic function by tissue Doppler imaging and clinical status in children with hypertrophic cardiomyopathy. *Circulation*. 2004;109(14):1756-1762. [CrossRef]
212. Bayrak F, Kahveci G, Mutlu B, Sonmez K, Degertekin M. Tissue Doppler imaging to predict clinical course of patients with hypertrophic cardiomyopathy. *Eur J Echocardiogr*. 2008;9(2):278-283. [CrossRef]
213. Wabich E, Dorniak K, Zienciuk-Krajka A, Nowak R, Raczak G, Daniłowicz-Szymanowicz L. Segmental longitudinal strain as the most accurate predictor of the patchy pattern late gadolinium enhancement in hypertrophic cardiomyopathy. *J Cardiol*. 2021;77(5):475-481. [CrossRef]
214. Serri K, Reant P, Lafitte M, et al. Global and regional myocardial function quantification by two-dimensional strain: application in hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2006;47(6):1175-1181. [CrossRef]
215. Hartlage GR, Kim JH, Strickland PT, et al. The prognostic value of standardized reference values for speckle-tracking global longitudinal strain in hypertrophic cardiomyopathy. *Int J Cardiovasc Imaging*. 2015;31(3):557-565. [CrossRef]
216. Sun JP, Xu TY, Ni XD, et al. Echocardiographic strain in hypertrophic cardiomyopathy and hypertensive left ventricular hypertrophy. *Echocardiography*. 2019;36(2):257-265. [CrossRef]
217. Maron BJ, Olivetto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. *Circulation*. 2000;102(8):858-864. [CrossRef]
218. Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 1986;8(3):545-557. [CrossRef]
219. Patten M, Pecha S, Aydin A. Atrial Fibrillation in Hypertrophic Cardiomyopathy: Diagnosis and Considerations for Management. *J Atr Fibrillation*. 2018;10(5):1556. [CrossRef]

220. Finocchiaro G, Papadakis M, Tanzarella G, et al. Sudden Death Can Be the First Manifestation of Hypertrophic Cardiomyopathy: Data From a United Kingdom Pathology Registry. *JACC Clin Electrophysiol.* 2019;5(2):252-254. [CrossRef]
221. Weissler-Snir A, Allan K, Cunningham K, et al. Hypertrophic Cardiomyopathy-Related Sudden Cardiac Death in Young People in Ontario. *Circulation.* 2019;140(21):1706-1716. [CrossRef]
222. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2011;58(25):2703-2738. [CrossRef]
223. Authors/Task Force members; Elliott PM, Anastakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). *Eur Heart J.* 2014;35(39):2733-2779. [CrossRef]
224. Marstrand P, Han L, Day SM, et al.; SHaRe Investigators. Hypertrophic Cardiomyopathy with Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry. *Circulation.* 2020;141(17):1371-1383. [CrossRef]
225. Lee HJ, Kim HK, Lee SC, et al. Performance of 2020 AHA/ACC HCM Guidelines and Incremental Value of Myocardial Strain for Predicting SCD. *JACC Asia.* 2023;4(1):10-22. [CrossRef]
226. Papanastasiou CA, Zegkos T, Karamitsos TD, et al. Prognostic role of left ventricular apical aneurysm in hypertrophic cardiomyopathy: A systematic review and meta-analysis. *Int J Cardiol.* 2021;332:127-132. [CrossRef]
227. Girolami F, Iascone M, Tomberli B, et al. Novel α -actinin 2 variant associated with familial hypertrophic cardiomyopathy and juvenile atrial arrhythmias: a massively parallel sequencing study. *Circ Cardiovasc Genet.* 2014;7(6):741-750. [CrossRef]
228. Orenes-Piñero E, Hernández-Romero D, Romero-Aniorte AI, et al. Prognostic value of two polymorphisms in non-sarcomeric genes for the development of atrial fibrillation in patients with hypertrophic cardiomyopathy. *QJM.* 2014;107(8):613-621. [CrossRef]
229. Nistri S, Olivetto I, Betocchi S, et al. Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). *Am J Cardiol.* 2006;98(7):960-965. [CrossRef]
230. Zegkos T, Ntelios D, Parcharidou D, et al. The Prognostic Value of Left Atrial Deformation Parameters for Sudden Arrhythmic Events in Hypertrophic Cardiomyopathy. *J Am Soc Echocardiogr.* 2020;33(10):1276-1277.e1. [CrossRef]
231. Pedrotti P, Vittori C, Facchetti R, et al. Prognostic impact of late gadolinium enhancement in the risk stratification of heart transplant patients. *Eur Heart J Cardiovasc Imaging.* 2017;18(2):130-137. [CrossRef]
232. Chan RH, Maron BJ, Olivetto I, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. *Circulation.* 2014;130(6):484-495. [CrossRef]
233. Achim A, Serban AM, Mot SDC, Leibundgut G, Marc M, Sigwart U. Alcohol septal ablation in hypertrophic cardiomyopathy: For which patients? *ESC Heart Fail.* 2023;10(3):1570-1579. [CrossRef]
234. Durand E, Mousseaux E, Coste P, et al. Non-surgical septal myocardial reduction by coil embolization for hypertrophic obstructive cardiomyopathy: early and 6 months follow-up. *Eur Heart J.* 2008;29(3):348-355. [CrossRef]
235. Lawrenz T, Borchert B, Leuner C, et al. Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy: acute results and 6 months' follow-up in 19 patients. *J Am Coll Cardiol.* 2011;57(5):572-576. [CrossRef]
236. Goldie FC, Lee MMY, Coats CJ, Nordin S. Advances in Multi-Modality Imaging in Hypertrophic Cardiomyopathy. *J Clin Med.* 2024;13(3):842. [CrossRef]
237. Sherid MV, Gunsburg DZ, Moldenhauer S, Pearle G. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy. *J Am Coll Cardiol.* 2000;36(4):1344-1354. [CrossRef]
238. Dong T, Gilliland Y, Kramer CM, Theodore A, Desai M. Multimodality imaging of hypertrophic cardiomyopathy. *Prog Cardiovasc Dis.* 2023;80:14-24. [CrossRef]
239. Maron MS, Olivetto I, Harrigan C, et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. *Circulation.* 2011;124(1):40-47. [CrossRef]
240. La Canna G, Scarfò I, Arendar I, et al. Targeting Alcohol Septal Ablation in Patients with Obstructive Hypertrophic Cardiomyopathy Candidates for Surgical Myectomy: Added Value of Three-Dimensional Intracoronary Myocardial Contrast Echocardiography. *J Clin Med.* 2021;10(10):2166. [CrossRef]
241. Carasso S, Marmor DB, Shuvy M. Transcatheter Edge to Edge Mitral Valve Repair for Mitral Regurgitation in Hypertrophic Cardiomyopathy: A Case Series. *Can J Cardiol.* 2024;40(2):326-328. [CrossRef]
242. Cooper RM, Binukrishnan SR, Shahzad A, Hasleton J, Sigwart U, Stables RH. Computed tomography angiography planning identifies the target vessel for optimum infarct location and improves clinical outcome in alcohol septal ablation for hypertrophic obstructive cardiomyopathy. *EuroIntervention.* 2017;12(18):e2194-e2203. [CrossRef]
243. Cannon RO 3rd, Dilsizian V, O'Gara PT, et al. Impact of surgical relief of outflow obstruction on thallium perfusion abnormalities in hypertrophic cardiomyopathy. *Circulation.* 1992;85(3):1039-1045. [CrossRef]
244. Abazid RM, Romsa JG, Warrington JC, Akincioglu C, Stodilka RZ, Vezina WC. Complementary role of hybrid imaging with SPECT myocardial perfusion and coronary CT angiography in hypertrophic cardiomyopathy. *J Nucl Cardiol.* 2022;29(5):2716-2720. [CrossRef]
245. Fagard R. Athlete's heart. *Heart.* 2003;89(12):1455-1461. [CrossRef]
246. Pelliccia A, Caselli S, Sharma S, et al.; Internal reviewers for EAPC and EACVI. European Association of Preventive Cardiology (EAPC) and European Association of Cardiovascular Imaging (EACVI) joint position statement: recommendations for the indication and interpretation of cardiovascular imaging in the evaluation of the athlete's heart. *Eur Heart J.* 2018;39(21):1949-1969. [CrossRef]
247. Pelliccia A, Culasso F, Di Paolo FM, Maron BJ. Physiologic left ventricular cavity dilatation in elite athletes. *Ann Intern Med.* 1999;130(1):23-31. [CrossRef]
248. Maron BJ, Levine BD, Washington RL, Baggish AL, Kovacs RJ, Maron MS; American Heart Association Electrocardiography and Arrhythmias Committee of Council on Clinical Cardiology, Council on Cardiovascular Disease in Young, Council on Cardiovascular and Stroke Nursing, Council on Functional Genomics and Translational Biology, and American College of Cardiology. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 2: Preparticipation Screening for Cardiovascular Disease in Competitive Athletes: A Scientific Statement From the American Heart Association and American College of Cardiology. *Circulation.* 2015;132(22):e267-e272. [CrossRef]
249. Martinez MW, Kim JH, Shah AB, et al. Exercise-Induced Cardiovascular Adaptations and Approach to Exercise and Cardiovascular Disease: JACC State-of-the-Art Review. *J Am Coll Cardiol.* 2021;78(14):1453-1470. [CrossRef]
250. Oxborough D, Augustine D, Gati S, et al. A guideline update for the practice of echocardiography in the cardiac screening of sports participants: a joint policy statement from the British Society of Echocardiography and Cardiac Risk in the Young. *Echo Res Pract.* 2018;5(1):G1-G10. [CrossRef]
251. Morganroth J, Maron BJ, Henry WL, Epstein SE. Comparative left ventricular dimensions in trained athletes. *Ann Intern Med.* 1975;82(4):521-524. [CrossRef]
252. D'Ascenzi F, Biella F, Lemme E, Maestrini V, Di Giacinto B, Pelliccia A. Female Athlete's Heart: Sex Effects on Electrical and Structural Remodeling. *Circ Cardiovasc Imaging.* 2020;13(12):e011587. [CrossRef]

253. D'Ascenzi F, Valentini F, Pistori S, et al. Causes of sudden cardiac death in young athletes and non-athletes: systematic review and meta-analysis: Sudden cardiac death in the young. *Trends Cardiovasc Med*. 2022;32(5):299–308. [\[CrossRef\]](#)
254. Corrado D, Basso C, Rizzoli G, Schiavon M, Thiene G. Does sports activity enhance the risk of sudden death in adolescents and young adults? *J Am Coll Cardiol*. 2003;42(11):1959–1963. [\[CrossRef\]](#)
255. Paterick TE, Gordon T, Spiegel D. Echocardiography: profiling of the athlete's heart. *J Am Soc Echocardiogr*. 2014;27(9):940–948. [\[CrossRef\]](#)
256. Ricci F, Sutton R, Palermi S, et al. Prognostic significance of noncardiac syncope in the general population: A systematic review and meta-analysis. *J Cardiovasc Electrophysiol*. 2018;29(12):1641–1647. [\[CrossRef\]](#)
257. Steding K, Engblom H, Buhre T, et al. Relation between cardiac dimensions and peak oxygen uptake. *J Cardiovasc Magn Reson*. 2010;12(1):8. [\[CrossRef\]](#)
258. Pelliccia A, Dipaolo FM. Cardiac remodeling in women athletes and implications for cardiovascular screening. *Med Sci Sports Exerc*. 2005;37(8):1436–1439. [\[CrossRef\]](#)
259. Pelliccia A, Maron BJ, De Luca R, Di Paolo FM, Spataro A, Culasso F. Remodeling of left ventricular hypertrophy in elite athletes after long-term deconditioning. *Circulation*. 2002;105(8):944–949. [\[CrossRef\]](#)
260. Aberger E, Chatellier G, Hagege AA, et al. Serial left ventricular adaptations in world-class professional cyclists: implications for disease screening and follow-up. *J Am Coll Cardiol*. 2004;44(1):144–149. [\[CrossRef\]](#)
261. Cardim N, Oliveira AG, Longo S, et al. Doppler tissue imaging: regional myocardial function in hypertrophic cardiomyopathy and in athlete's heart. *J Am Soc Echocardiogr*. 2003;16(3):223–232. [\[CrossRef\]](#)
262. Pelliccia A, Maron BJ, Di Paolo FM, et al. Prevalence and clinical significance of left atrial remodeling in competitive athletes. *J Am Coll Cardiol*. 2005;46(4):690–696. [\[CrossRef\]](#)
263. Engel DJ, Schwartz A, Homma S. Athletic Cardiac Remodeling in US Professional Basketball Players. *JAMA Cardiol*. 2016;1(1):80–87. [\[CrossRef\]](#)
264. Braverman AC, Harris KM, Kovacs RJ, Maron BJ; American Heart Association Electrocardiography and Arrhythmias Committee of Council on Clinical Cardiology, Council on Cardiovascular Disease in Young, Council on Cardiovascular and Stroke Nursing, Council on Functional Genomics and Translational Biology, and American College of Cardiology. Eligibility and Disqualification Recommendations for Competitive Athletes with Cardiovascular Abnormalities: Task Force 7: Aortic Diseases, Including Marfan Syndrome: A Scientific Statement From the American Heart Association and American College of Cardiology. *Circulation*. 2015;132(22):e303–e309. [\[CrossRef\]](#)
265. D'Ascenzi F, Picicchio C, Caselli S, Di Paolo FM, Spataro A, Pelliccia A. RV Remodeling in Olympic Athletes. *JACC Cardiovasc Imaging*. 2017;10(4):385–393. [\[CrossRef\]](#)
266. Afonso L, Kondur A, Simegn M, et al. Two-dimensional strain profiles in patients with physiological and pathological hypertrophy and preserved left ventricular systolic function: a comparative analyses. *BMJ Open*. 2012;2(4):e001390. [\[CrossRef\]](#)
267. Weiner RB, Hutter AM Jr, Wang F, et al. The impact of endurance exercise training on left ventricular torsion. *JACC Cardiovasc Imaging*. 2010;3(10):1001–1009. [\[CrossRef\]](#)
268. Notomi Y, Martin-Miklovic MG, Oryszak SJ, et al. Enhanced ventricular untwisting during exercise: a mechanistic manifestation of elastic recoil described by Doppler tissue imaging. *Circulation*. 2006;113(21):2524–2533. [\[CrossRef\]](#)
269. D'Andrea A, Riegler L, Morra S, et al. Right ventricular morphology and function in top-level athletes: a three-dimensional echocardiographic study. *J Am Soc Echocardiogr*. 2012;25(12):1268–1276. [\[CrossRef\]](#)
270. Esposito R, Galderisi M, Schiano-Lomoriello V, et al. Nonsymmetric myocardial contribution to supranormal right ventricular function in the athlete's heart: combined assessment by speckle tracking and real time three-dimensional echocardiography. *Echocardiography*. 2014;31(8):996–1004. [\[CrossRef\]](#)
271. Scharhag J, Schneider G, Urhausen A, Rochette V, Kramann B, Kindermann W. Athlete's heart: right and left ventricular mass and function in male endurance athletes and untrained individuals determined by magnetic resonance imaging. *J Am Coll Cardiol*. 2002;40(10):1856–1863. [\[CrossRef\]](#)
272. Riding NR, Sharma S, Salah O, et al. Systematic echocardiography is not efficacious when screening an ethnically diverse cohort of athletes in West Asia. *Eur J Prev Cardiol*. 2015;22(2):263–270. [\[CrossRef\]](#)
273. Baggish AL, Yared K, Weiner RB, et al. Differences in cardiac parameters among elite rowers and subelite rowers. *Med Sci Sports Exerc*. 2010;42(6):1215–1220. [\[CrossRef\]](#)
274. Bauce B, Frigo G, Benini G, et al. Differences and similarities between arrhythmogenic right ventricular cardiomyopathy and athlete's heart adaptations. *Br J Sports Med*. 2010;44(2):148–154. [\[CrossRef\]](#)
275. Altin C, Okyay K, Kış M, et al. The Safety and Tolerability of Nebivolol in Hypertensive Patients with Coronary Artery Disease and Left Ventricular Ejection Fraction \geq 40%: A Population-Based Cohort Study (Nebivolol-TR Study). *Turk Kardiyol Dern Ars*. 2022;50(8):568–575. [\[CrossRef\]](#)
276. Drazner MH. The progression of hypertensive heart disease. *Circulation*. 2011;123(3):327–334. [\[CrossRef\]](#)
277. Gaudron PD, Liu D, Scholz F, et al. The septal bulge—an early echocardiographic sign in hypertensive heart disease. *J Am Soc Hypertens*. 2016;10(1):70–80. [\[CrossRef\]](#)
278. Kis M, Dogan Y, Yildirim A, et al. Evaluation of demographic, clinical, and aetiological data of patients admitted to cardiology clinics and diagnosed with left ventricular hypertrophy in Turkish population (LVH-TR). *Acta Cardiol*. 2022;77(9):836–845. [\[CrossRef\]](#)
279. Messerli FH, Rimoldi SF, Bangalore S. The Transition From Hypertension to Heart Failure: Contemporary Update. *JACC Heart Fail*. 2017;5(8):543–551. [\[CrossRef\]](#)
280. Moura B, Aimo A, Al-Mohammad A, et al. Diagnosis and management of patients with left ventricular hypertrophy: Role of multimodality cardiac imaging. A scientific statement of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail*. 2023;25(9):1493–1506. [\[CrossRef\]](#)
281. Ko SM, Hwang SH, Lee HJ. Role of Cardiac Computed Tomography in the Diagnosis of Left Ventricular Myocardial Diseases. *J Cardiovasc Imaging*. 2019;27(2):73–92. [\[CrossRef\]](#)
282. Rodrigues JC, Amadu AM, Dastidar AG, et al. Prevalence and predictors of asymmetric hypertensive heart disease: insights from cardiac and aortic function with cardiovascular magnetic resonance. *Eur Heart J Cardiovasc Imaging*. 2016;17(12):1405–1413. [\[CrossRef\]](#)
283. Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. *Hypertension*. 2009;54(5):1084–1091. [\[CrossRef\]](#)
284. Tuseth N, Cramariu C, Rieck A, Wachtell K, Gerds E. Asymmetric septal hypertrophy: a marker of hypertension in aortic stenosis (a SEAS substudy). *Blood Press*. 2010;19(3):140–144. [\[CrossRef\]](#)
285. Ostman-Smith I. Cardiac sympathetic nerves as the final common pathway in the induction of adaptive cardiac hypertrophy. *Clin Sci (Lond)*. 1981;61(3):265–272. [\[CrossRef\]](#)
286. Sadoshima J, Izumo S. Molecular characterization of angiotensin II – induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. *Circ Res*. 1993;73(3):413–423. [\[CrossRef\]](#)
287. Canepa M, Malti O, David M, et al. Prevalence, Clinical Correlates, and Functional Impact of Subaortic Ventricular Septal Bulge (from the Baltimore Longitudinal Study of Aging). *Am J Cardiol*. 2014;114(5):796–802. [\[CrossRef\]](#)
288. Santos M, Shah AM. Alterations in cardiac structure and function in hypertension. *Curr Hypertens Rep*. 2014;16(5):428. [\[CrossRef\]](#)
289. Escobar E. Hypertension and coronary heart disease. *J Hum Hypertens*. 2002;16(Suppl1):S61–63. [\[CrossRef\]](#)
290. Wachtell K, Smith G, Gerds E, et al. Left ventricular filling patterns in patients with systemic hypertension and left ventricular

- hypertrophy (the LIFE study). Losartan Intervention For Endpoint. *Am J Cardiol*. 2000;85(4):466-472. [\[CrossRef\]](#)
291. Dini FL, Galderisi M, Nistri S, et al. Abnormal left ventricular longitudinal function assessed by echocardiographic and tissue Doppler imaging is a powerful predictor of diastolic dysfunction in hypertensive patients: the SPHERE study. *Int J Cardiol*. 2013;168(4):3351-3358. [\[CrossRef\]](#)
292. Smiseth OA, Morris DA, Cardim N, et al. Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*. 2022;23(2):e34-e61. [\[CrossRef\]](#)
293. Galderisi M, Lomoriello VS, Santoro A, et al. Differences of myocardial systolic deformation and correlates of diastolic function in competitive rowers and young hypertensives: a speckletracking echocardiography study. *J Am Soc Echocardiogr*. 2010;23(11):1190-1198. [\[CrossRef\]](#)
294. Tanaka H. Utility of strain imaging in conjunction with heart failure stage classification for heart failure patient management. *J Echocardiogr*. 2019;17(1):17-24. [\[CrossRef\]](#)
295. Bendiab STN, Meziane-Tani A, Ouabdesselam S, et al. Factors associated with global longitudinal strain decline in hypertensive patients with normal left ventricular ejection fraction. *Eur J Prev Cardiol*. 2017;24(14):1463-1472. [\[CrossRef\]](#)
296. Narayanan A, Aurigemma G, Chinali M, et al. Cardiac mechanics in mild hypertensive heart disease: a specklestrain imaging study. *Circ Cardiovasc Imaging*. 2009;2(5):382-390. [\[CrossRef\]](#)
297. Galderisi M, Esposito R, Schiano-Lomoriello V, et al. Correlates of global area strain in native hypertensive patients: a three dimensional speckle-tracking echocardiography study. *Eur Heart J Cardiovasc Imaging*. 2012;13(9):730-738. [\[CrossRef\]](#)
298. Cameli M, Lisi M, Righini FM, Massoni A, Mondillo S. Left ventricular remodeling and torsion dynamics in hypertensive patients. *Int J Cardiovasc Imaging*. 2013;29(1):79-86. [\[CrossRef\]](#)
299. Treibel TA, Bandula S, Fontana M, et al. Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis. *J Cardiovasc Comput Tomogr*. 2015;9(6):585-592. [\[CrossRef\]](#)
300. Asferg C, Usinger L, Kristensen TS, Abdulla J. Accuracy of multi-slice computed tomography for measurement of left ventricular ejection fraction compared with cardiac magnetic resonance imaging and two-dimensional transthoracic echocardiography: a systematic review and meta-analysis. *Eur J Radiol*. 2012;81(5):e757-762. [\[CrossRef\]](#)
301. Zhou W, Brown JM, Bajaj NS, et al. Hypertensive coronary microvascular dysfunction: a subclinical marker of end organ damage and heart failure. *Eur Heart J*. 2020;41(25):2366-2375. [\[CrossRef\]](#)
302. Friedrich MG, Dahlöf B, Sechtem U, Unger T, Knecht M, Dietz R; TELMAR Investigators. Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design. *J Renin Angiotensin Aldosterone Syst*. 2003;4(4):234-243. [\[CrossRef\]](#)
303. Tadic M, Cuspidi C, Plein S, et al. Comprehensive assessment of hypertensive heart disease: cardiac magnetic resonance in focus. *Heart Fail Rev*. 2021;26(6):1383-1390. [\[CrossRef\]](#)
304. Kramer CM, Barkhausen J, Bucciarelli-Ducci C, Flamm SD, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update. *J Cardiovasc Magn Reson*. 2020;22(1):17. [\[CrossRef\]](#)
305. Nguyen J, Weber J, Hsu B, Mulyala RR, Wang L, Cao JJ. Comparing left atrial indices by CMR in association with left ventricular diastolic dysfunction and adverse clinical outcomes. *Sci Rep*. 2021;11(1):21331. [\[CrossRef\]](#)
306. Sironi AM, Pingitore A, Ghione S, et al. Early hypertension is associated with reduced regional cardiac function, insulin resistance, epicardial, and visceral fat. *Hypertension*. 2008;51(2):282-288. [\[CrossRef\]](#)
307. Dong T, Faaborg-Andersen C, Garcia M, et al. Multimodality cardiovascular imaging in hypertension. *Curr Opin Cardiol*. 2023;38(4):287-296. [\[CrossRef\]](#)
308. Rudolph A, Abdel-Aty H, Bohl S, et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy: relation to remodeling. *J Am Coll Cardiol*. 2009;53(3):284-291. [\[CrossRef\]](#)
309. Moreo A, Ambrosio G, De Chiara B, et al. Influence of myocardial fibrosis on left ventricular diastolic function: noninvasive assessment by cardiac magnetic resonance and echo. *Circ Cardiovasc Imaging*. 2009;2(6):437-443. [\[CrossRef\]](#)
310. Schumann CL, Jaeger NR, Kramer CM. Recent Advances in Imaging of Hypertensive Heart Disease. *Curr Hypertens Rep*. 2019;21(1):3. [\[CrossRef\]](#)
311. Treibel TA, Zemrak F, Sado DM, et al. Extracellular volume quantification in isolated hypertension - changes at the detectable limits? *J Cardiovasc Magn Reson*. 2015;17(1):74. [\[CrossRef\]](#)
312. Leiner T, Bogaert J, Friedrich MG, et al. SCMR Position Paper (2020) on clinical indications for cardiovascular magnetic resonance. *J Cardiovasc Magn Reson*. 2020;22(1):76. [\[CrossRef\]](#)
313. Yiğiner O, Cingözbay BY, Uz O, Cebeci BS. An overlooked diagnosis on transthoracic echocardiography: apical hypertrophic cardiomyopathy. *Turk Kardiyol Dern Ars*. 2009;37(8):569-571.
314. Wicker P, Roudaut R, Haissaguere M, Villega-Arino P, Clementy J, Dalocchio M. Prevalence and significance of asymmetric septal hypertrophy in hypertension: an echocardiographic and clinical study. *Eur Heart J*. 1983;4(Suppl G):1-5. [\[CrossRef\]](#)
315. Nagakura T, Takeuchi M, Yoshitani H, et al. Hypertrophic cardiomyopathy is associated with more severe left ventricular dyssynchrony than is hypertensive left ventricular hypertrophy. *Echocardiography*. 2007;24(7):677-684. [\[CrossRef\]](#)
316. Rowin EJ, Maron BJ, Maron MS. The Hypertrophic Cardiomyopathy Phenotype Viewed Through the Prism of Multimodality Imaging: Clinical and Etiologic Implications. *JACC Cardiovasc Imaging*. 2020;13(9):2002-2016. [\[CrossRef\]](#)
317. Henein MY, Pilebro B, Lindqvist P. Disease progression in cardiac morphology and function in heart failure: ATTR cardiac amyloidosis versus hypertensive left ventricular hypertrophy. *Heart Vessels*. 2022;37(9):1562-1569. [\[CrossRef\]](#)
318. Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-Evidence base and standardized methods of imaging. *J Nucl Cardiol*. 2019;26(6):2065-2123. [\[CrossRef\]](#)
319. Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases. *Eur Heart J*. 2021;42(16):1554-1568. [\[CrossRef\]](#)
320. Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2018: Recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. *Amyloid*. 2018;25(4):215-219. [\[CrossRef\]](#)
321. Merlini G, Dispenzieri A, Sanchorawala V, et al. Systemic immunoglobulin light chain amyloidosis. *Nat Rev Dis Primers*. 2018;4(1):38. [\[CrossRef\]](#)
322. Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) cardiac amyloidosis: A review of diagnosis and therapy. *J Am Coll Cardiol*. 2016;68(12):1323-1341. [\[CrossRef\]](#)
323. Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: A review. *J Am Heart Assoc*. 2012;1(2):e000364. [\[CrossRef\]](#)
324. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidosis: Disease profiles and clinical courses of the 3 main types. *Circulation*. 2009;120(13):1203-1212. [\[CrossRef\]](#)
325. Oerlemans MIFJ, Rutten KHG, Minnema MC, Raymakers RAP, Asselbergs FW, de Jonge N. Cardiac amyloidosis: The need for early diagnosis. *Neth Heart J*. 2019;27(11):525-536. [\[CrossRef\]](#)
326. Siddiqi OK, Ruberg FL. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. *Trends Cardiovasc Med*. 2018;28(1):10-21. [\[CrossRef\]](#)

327. Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. *Cardiovasc Res*. 2023;118(18):3517–3535. [\[CrossRef\]](#)
328. González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. *Eur Heart J*. 2015;36(38):2585–2594. [\[CrossRef\]](#)
329. Donnelly JP, Hanna M. Cardiac amyloidosis: An update on diagnosis and treatment. *Cleve Clin J Med*. 2017;84(12 Suppl 3):12–26. [\[CrossRef\]](#)
330. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. *J Am Coll Cardiol*. 2019;73(22):2872–2891. [\[CrossRef\]](#)
331. Sperry BW, Vranian MN, Hachamovitch R, et al. Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings. *Int J Cardiol*. 2016;214:477–481. [\[CrossRef\]](#)
332. Cyrille NB, Goldsmith J, Alvarez J, Maurer MS. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. *Am J Cardiol*. 2014;114(7):1089–1093. [\[CrossRef\]](#)
333. Damy T, Maurer MS, Rapezzi C, et al. Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy. *Open Heart*. 2016;3(1):e000289. [\[CrossRef\]](#)
334. Hongo M, Yamamoto H, Kohda T, et al. Comparison of electrocardiographic findings in patients with AL (primary) amyloidosis and in familial amyloid polyneuropathy and anginal pain and their relation to histopathologic findings. *Am J Cardiol*. 2000;85(7):849–853. [\[CrossRef\]](#)
335. Sayed RH, Rogers D, Khan F, et al. A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. *Eur Heart J*. 2015;36(18):1098–1105. [\[CrossRef\]](#)
336. Varr BC, Zarafshar S, Coakley T, et al. Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. *Heart Rhythm*. 2014;11(1):158–162. [\[CrossRef\]](#)
337. Cuddy SAM, Chetrit M, Jankowski M, et al. Practical points for echocardiography in cardiac amyloidosis. *J Am Soc Echocardiogr*. 2022;35(9):A31–A40. [\[CrossRef\]](#)
338. Rapezzi C, Aimo A, Pavasini R. Longitudinal strain in the management of cardiac AL amyloidosis: Do we need it? *Eur Heart J*. 2022;43(4):342–344. [\[CrossRef\]](#)
339. Quarta CC, Solomon SD, Uraizee I, et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. *Circulation*. 2014;129(18):1840–1849. [\[CrossRef\]](#)
340. Koyama J, Ray-Sequin PA, Davidoff R, Falk RH. Usefulness of pulsed tissue Doppler imaging for evaluating systolic and diastolic left ventricular function in patients with AL (primary) amyloidosis. *Am J Cardiol*. 2002;89(9):1067–1071. [\[CrossRef\]](#)
341. Tendler A, Helmke S, Teruya S, Alvarez J, Maurer MS. The myocardial contraction fraction is superior to ejection fraction in predicting survival in patients with AL cardiac amyloidosis. *Amyloid*. 2015;22(1):61–66. [\[CrossRef\]](#)
342. Bellavia D, Pellikka PA, Dispenzieri A, et al. Comparison of right ventricular longitudinal strain imaging, tricuspid annular plane systolic excursion, and cardiac biomarkers for early diagnosis of cardiac involvement and risk stratification in primary systemic (AL) amyloidosis: A 5-year cohort study. *Eur Heart J Cardiovasc Imaging*. 2012;13(8):680–689. [\[CrossRef\]](#)
343. Nochioka K, Quarta CC, Claggett B, et al. Left atrial structure and function in cardiac amyloidosis. *Eur Heart J Cardiovasc Imaging*. 2017;18(10):1128–1137. [\[CrossRef\]](#)
344. Kwong RY, Heydari B, Abbasi S, et al. Characterization of cardiac amyloidosis by atrial late gadolinium enhancement using contrast-enhanced cardiac magnetic resonance imaging and correlation with left atrial conduit and contractile function. *Am J Cardiol*. 2015;116(4):622–629. [\[CrossRef\]](#)
345. Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, et al. Magnetic Resonance in Transthyretin Cardiac Amyloidosis. *Journal of the American College of Cardiology*. 2017;70(4):466–477. [\[CrossRef\]](#)
346. Karamitsos TD, Piechnik SK, Bannypersad SM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. *JACC Cardiovasc Imaging*. 2013;6(4):488–497. [\[CrossRef\]](#)
347. Fontana M, Bannypersad SM, Treibel TA, et al. Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: A cardiac MR imaging study. *Radiology*. 2015;277(2):388–397. [\[CrossRef\]](#)
348. Bannypersad SM, Fontana M, Maestrini V, et al. T1 mapping and survival in systemic light-chain amyloidosis. *Eur Heart J*. 2015;36(4):244–251. [\[CrossRef\]](#)
349. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. *Circulation*. 2005;111(2):186–193. [\[CrossRef\]](#)
350. Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. *Circulation*. 2015;132(16):1570–1579. [\[CrossRef\]](#)
351. Zhao L, Tian Z, Fang Q. Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: A systematic review and meta-analysis. *BMC Cardiovasc Disord*. 2016;16:129. [\[CrossRef\]](#)
352. Kotecha T, Martinez-Naharro A, Treibel TA, et al. Myocardial edema and prognosis in amyloidosis. *J Am Coll Cardiol*. 2018;71(25):2919–2931. [\[CrossRef\]](#)
353. Dzungu JN, Valencia O, Pinney JH, et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. *JACC Cardiovasc Imaging*. 2014;7(2):133–142. [\[CrossRef\]](#)
354. Hutt DF, Fontana M, Burniston M, et al. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. *Eur Heart J Cardiovasc Imaging*. 2017;18(12):1344–1350. [\[CrossRef\]](#)
355. Ioannou A, Patel RK, Razvi Y, et al. Multi-imaging characterization of cardiac phenotype in different types of amyloidosis. *JACC Cardiovasc Imaging*. 2023;16(4):464–477. [\[CrossRef\]](#)
356. Quarta CC, Gonzalez-Lopez E, Gilbertson JA, et al. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. *Eur Heart J*. 2017;38(24):1905–1908. [\[CrossRef\]](#)
357. Long TE, Indridason OS, Palsson R, et al. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study. *Blood Cancer J*. 2022;12(9):133. [\[CrossRef\]](#)
358. Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. *Eur Heart J*. 2018;39(30):2799–2806. [\[CrossRef\]](#)
359. Siddiqi OK, Sanchorawala V, Ruberg FL. Echocardiography and survival in light chain cardiac amyloidosis: Back to basics. *Circ Cardiovasc Imaging*. 2018;11(5):e007826. [\[CrossRef\]](#)
360. Cohen OC, Ismael A, Pawarova B, et al. Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis. *Eur Heart J*. 2022;43(4):333–341. [\[CrossRef\]](#)
361. Boretto P, Patel NH, Patel K, et al. Prognosis prediction in cardiac amyloidosis by cardiac magnetic resonance imaging: a systematic review with meta-analysis. *Eur Heart J Open*. 2023;3(5):oead092. [\[CrossRef\]](#)
362. Griffin JM, Rosenblum H, Maurer MS. Pathophysiology and therapeutic approaches to cardiac amyloidosis. *Circ Res*. 2021;128(10):1554–1575. [\[CrossRef\]](#)
363. Sekijima Y, Wiseman RL, Matteson J, et al. The biological and chemical basis for tissue-selective amyloid disease. *Cell*. 2005;121(1):73–85. [\[CrossRef\]](#)
364. Maurer MS, Hanna M, Grogan M, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). *J Am Coll Cardiol*. 2016;68(2):161–172. [\[CrossRef\]](#)
365. Coelho T, Maurer MS, Suhr OB. THAOS – The Transthyretin Amyloidosis Outcomes Survey: Initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. *Curr Med Res Opin*. 2013;29(1):63–76. [\[CrossRef\]](#)
366. Aimo A, Merlo M, Porcari A, et al. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis

- of screening studies. *Eur J Heart Fail.* 2022;24(12):2342-2351. [\[CrossRef\]](#)
367. Castaño A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. *Eur Heart J.* 2017;38(38):2879-2887. [\[CrossRef\]](#)
368. Moody WE, Turvey-Haigh L, Knight D, et al. British Society of Echocardiography guideline for the transthoracic echocardiographic assessment of cardiac amyloidosis. *Echo Res Pract.* 2023;10(1):13. [\[CrossRef\]](#)
369. Falk RH, Quarta CC. Echocardiography in cardiac amyloidosis. *Heart Fail Rev.* 2015;20(2):125-131. [\[CrossRef\]](#)
370. Oda S, Kidoh M, Nagayama Y, et al. Trends in diagnostic imaging of cardiac amyloidosis: Emerging knowledge and concepts. *RadioGraphics.* 2020;40(4):961-981. [\[CrossRef\]](#)
371. Aimo A, Camerini L, Fabiani I, et al. Valvular heart disease in patients with cardiac amyloidosis. *Heart Fail Rev.* 2024;29(1):65-77. [\[CrossRef\]](#)
372. Boldrini M, Cappelli F, Chacko L, et al. multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis. *JACC Cardiovasc Imaging.* 2020;13(4):909-920. [\[CrossRef\]](#)
373. Pagourelas ED, Mirea O, Duchenne J, et al. Echo parameters for differential diagnosis in cardiac amyloidosis: A head-to-head comparison of deformation and nondeformation parameters. *Circ Cardiovasc Imaging.* 2017;10(3):e005588. [\[CrossRef\]](#)
374. Chacko L, Martone R, Bandera F, et al. Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. *Eur Heart J.* 2020;41(14):1439-1447. [\[CrossRef\]](#)
375. Merlo M, Pagura L, Porcari A, et al. Unmasking the prevalence of amyloid cardiomyopathy in the real world: Results from Phase 2 of the AC-TIVE study, an Italian nationwide survey. *Eur J Heart Fail.* 2022;24(8):1377-1386. [\[CrossRef\]](#)
376. Davies DR, Redfield MM, Scott CG, et al. A simple score to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. *JAMA Cardiol.* 2022;7(10):1036-1044. [\[CrossRef\]](#)
377. Goto S, Mahara K, Beussink-Nelson L, et al. Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms. *Nat Commun.* 2021;12(1):2726. [\[CrossRef\]](#)
378. Wu ZW, Zheng JL, Kuang L, Yan H. Machine learning algorithms to automate differentiating cardiac amyloidosis from hypertrophic cardiomyopathy. *Int J Cardiovasc Imaging.* 2023;39(2):339-348. [\[CrossRef\]](#)
379. Bhandari AK, Nanda NC. Myocardial texture characterization by two-dimensional echocardiography. *Am J Cardiol.* 1983;51(5):817-825. [\[CrossRef\]](#)
380. Vidal-Perez R, Vázquez-García R, Barge-Caballero G, et al. Diagnostic and prognostic value of cardiac imaging in amyloidosis. *World J Cardiol.* 2020;12(12):599-614. [\[CrossRef\]](#)
381. Knight DS, Zumbo G, Barcella W, et al. Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles. *JACC Cardiovasc Imaging.* 2019;12(5):823-833. [\[CrossRef\]](#)
382. Pozo E, Kanwar A, Deochand R, et al. Cardiac magnetic resonance evaluation of left ventricular remodelling distribution in cardiac amyloidosis. *Heart.* 2014;100(21):1688-1695. [\[CrossRef\]](#)
383. Wan K, Sun J, Yang D, et al. Left ventricular myocardial deformation on cine MR images: Relationship to severity of disease and prognosis in light-chain amyloidosis. *Radiology.* 2018;288(1):73-80. [\[CrossRef\]](#)
384. Fontana M, Banyersad SM, Treibel TA, et al. Native T1 mapping in transthyretin amyloidosis. *JACC Cardiovasc Imaging.* 2014;7(2):157-165. [\[CrossRef\]](#)
385. Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. *J Cardiovasc Magn Reson.* 2008;10(1):54. [\[CrossRef\]](#)
386. Fontana M, White SK, Banyersad SM, et al. Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR. *J Cardiovasc Magn Reson.* 2012;14(1):88. [\[CrossRef\]](#)
387. Banyersad SM, Sado DM, Flett AS, et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis. *Circ Cardiovasc Imaging.* 2013;6(1):34-39. [\[CrossRef\]](#)
388. Bohnen S, Radunski UK, Lund GK, et al. Performance of T1 and T2 mapping cardiovascular magnetic resonance to detect active myocarditis in patients with recent-onset heart failure. *Circ Cardiovasc Imaging.* 2015;8(6):e003073. [\[CrossRef\]](#)
389. Ridouani F, Damy T, Tacher V, et al. Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis. *J Cardiovasc Magn Reson.* 2018;20(1):58. [\[CrossRef\]](#)
390. Razvi Y, Patel RK, Fontana M, Gillmore JD. Cardiac amyloidosis: A review of current imaging techniques. *Front Cardiovasc Med.* 2021;8:751293. [\[CrossRef\]](#)
391. Sperry BW, Reyes BA, Ikram A, et al. Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release. *J Am Coll Cardiol.* 2018;72(17):2040-2050. [\[CrossRef\]](#)
392. Bravo PE, Dorbala S. Targeted nuclear imaging probes for cardiac amyloidosis. *Curr Cardiol Rep.* 2017;19(7):59. [\[CrossRef\]](#)
393. Dorbala S, Vangala D, Semer J, et al. Imaging cardiac amyloidosis: A pilot study using 18F-florbetapir positron emission tomography. *Eur J Nucl Med Mol Imaging.* 2014;41(9):1652-1662. [\[CrossRef\]](#)
394. Park MA, Padera RF, Belanger A, et al. 18F-florbetapir binds specifically to myocardial light chain and transthyretin amyloid deposits. *Circ Cardiovasc Imaging.* 2015;8(8):e002954. [\[CrossRef\]](#)
395. Antoni G, Lubberink M, Estrada S, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. *J Nucl Med.* 2013;54(2):213-220. [\[CrossRef\]](#)
396. Kittleson MM, Ruberg FL, Ambardekar AV, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol.* 2023;81:1076-1126. [\[CrossRef\]](#)
397. Mehta A, Widmer U. Natural history of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, eds. *Fabry Disease: Perspectives from 5 Years of FOS.* Oxford: Oxford PharmaGenesis; 2006.
398. Kim WS, Kim HS, Shin J, et al. Prevalence of Fabry disease in Korean men with left ventricular hypertrophy. *J Korean Med Sci.* 2019;34(7):e63. [\[CrossRef\]](#)
399. Clarke JT. Narrative review: Fabry disease. *Ann Intern Med.* 2007;146(6):425-433. [\[CrossRef\]](#)
400. Doheny D, Srinivasan R, Pagant S, Chen B, Yasuda M, Desnick RJ. Fabry disease: Prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995-2017. *J Med Genet.* 2018;55(4):261-268. [\[CrossRef\]](#)
401. Echevarria L, Benistan K, Toussaint A, et al. X-chromosome inactivation in female patients with Fabry disease. *Clin Genet.* 2016;89(1):44-54. [\[CrossRef\]](#)
402. Dobrovolny R, Dvorakova L, Ledvinova J, et al. Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population. *J Mol Med (Berl).* 2005;83(8):647-654. [\[CrossRef\]](#)
403. Mehta A, Clarke JT, Giugliani R, et al. Natural course of Fabry disease: Changing pattern of causes of death in FOS - Fabry Outcome Survey. *J Med Genet.* 2009;46(8):548-552. [\[CrossRef\]](#)
404. Arends M, Wanner C, Hughes D, et al. Characterization of classical and nonclassical Fabry disease: A multicenter study. *J Am Soc Nephrol.* 2017;28(5):1631-1641. [\[CrossRef\]](#)
405. Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: Management and treatment recommendations for adult patients. *Mol Genet Metab.* 2018;123(4):416-427. [\[CrossRef\]](#)
406. Paim-Marques L, de Oliveira RJ, Appenzeller S. Multidisciplinary Management of Fabry Disease: Current Perspectives. *J Multidiscip Healthc.* 2022;15:485-495. [\[CrossRef\]](#)
407. Kampmann C, Linhart A, Baehner F, et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. *Int J Cardiol.* 2008;130(3):367-373. [\[CrossRef\]](#)

408. Hagège A, Réant P, Habib G, et al. Fabry disease in cardiology practice: Literature review and expert point of view. *Arch Cardiovasc Dis.* 2019;112(4):278–287. [CrossRef]
409. Stiles AR, Zhang H, Dai J, et al. A comprehensive testing algorithm for the diagnosis of Fabry disease in males and females. *Mol Genet Metab.* 2020;130(3):209–214. [CrossRef]
410. Niemann M, Rolfes A, Störk S, et al. Gene mutations versus clinically relevant phenotypes: Lyso-Gb3 defines Fabry disease. *Circ Cardiovasc Genet.* 2014;7(1):8–16. [CrossRef]
411. Smid BE, van der Tol L, Cecchi F, et al. Uncertain diagnosis of Fabry disease: Consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. *Int J Cardiol.* 2014;177(2):400–408. [CrossRef]
412. Baig S, Edward NC, Kotecha D, et al. Ventricular arrhythmia and sudden cardiac death in Fabry disease: A systematic review of risk factors in clinical practice. *Europace.* 2018;20(F12):f153–f161. [CrossRef]
413. Akhtar MM, Elliott PM. Anderson–Fabry disease in heart failure. *Biophys Rev.* 2018;10(4):1107–1119. [CrossRef]
414. Frustaci A, Morgante E, Russo MA, et al. Pathology and function of conduction tissue in Fabry disease cardiomyopathy. *Circ Arrhythm Electrophysiol.* 2015;8(4):799–805. [CrossRef]
415. Pichette M, Serri K, Pagé M, Di LZ, Bichet DG, Poulin F. Impaired left atrial function in Fabry disease: A longitudinal speckle-tracking echocardiography study. *J Am Soc Echocardiogr.* 2017;30(2):170–179.e2. [CrossRef]
416. Putko BN, Wen K, Thompson RB, et al. Anderson–Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment. *Heart Fail Rev.* 2015;20(2):179–191. [CrossRef]
417. Yeung DF, Sirrs S, Tsang MYC, et al. Echocardiographic assessment of patients with Fabry disease. *J Am Soc Echocardiogr.* 2018;31(6):639–649.e2. [CrossRef]
418. Koskenvuo JW, Engblom E, Kantola IM, et al. Echocardiography in Fabry disease: Diagnostic value of endocardial border binary appearance. *Clin Physiol Funct Imaging.* 2009;29(3):177–180. [CrossRef]
419. Nordin S, Kozor R, Medina–Menacho K, et al. proposed stages of myocardial phenotype development in Fabry disease. *JACC Cardiovasc Imaging.* 2019;12(8 Pt 2):1673–1683. [CrossRef]
420. Torralba–Cabeza MÁ, Olivera S, Hughes DA, Pastores GM, Mateo RN, Pérez–Calvo JL. Cystatin C and NT–proBNP as prognostic biomarkers in Fabry disease. *Mol Genet Metab.* 2011;104(3):301–307. [CrossRef]
421. Coats CJ, Parisi V, Ramos M, et al. Role of serum N–terminal pro–brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with anderson–fabry disease. *Am J Cardiol.* 2013;111(1):111–117. [CrossRef]
422. Weidemann F, Strotmann JM, Niemann M, et al. Heart valve involvement in Fabry cardiomyopathy. *Ultrasound Med Biol.* 2009;35(5):730–735. [CrossRef]
423. Dobrowolski MK, Marczak M, Dąbrowski R. Aortic dissection four months after SARS–CoV–2 infection in a patient with Fabry disease whose targeted treatment was stopped 2 months earlier. *Kardiol Pol.* 2022;80(6):713–714. [CrossRef]
424. Djaileb L, Jankowski A, Riou L, Salvat M, Barone–Rochette G. Unusual SPECT myocardial perfusion imaging results in the setting of ventricular hypertrophy and non–obstructive coronary artery disease should suggest Anderson–Fabry disease. *Eur Heart J Cardiovasc Imaging.* 2019;20(9):1073. [CrossRef]
425. Replagal. Summary of product characteristics. Accessed April 03, 2024. https://www.ema.europa.eu/en/documents/product-information/replagal-epar-product-information_en.pdf.
426. Fabrazyme. Prescribing information. Accessed April 03, 2024. <https://products.sanofi.us/fabrazyme/fabrazyme.pdf>.
427. Mehta A, Beck M, Elliott P, et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: An analysis of registry data. *Lancet.* 2009;374(9706):1986–1996. [CrossRef]
428. Lenders M, Pollmann S, Terlinden M, Brand E. Pre-existing anti–drug antibodies in Fabry disease show less affinity for pegunigalsidase alfa. *Mol Ther Methods Clin Dev.* 2022;26:323–330. [CrossRef]
429. Shen JS, Busch A, Day TS, et al. Mannose receptor–mediated delivery of moss–made α –galactosidase A efficiently corrects enzyme deficiency in Fabry mice. *J Inherit Metab Dis.* 2016;39(2):293–303. [CrossRef]
430. Weidemann F, Niemann M, Breunig F, et al. Long–term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. *Circulation.* 2009;119(4):524–529. [CrossRef]
431. Hughes DA, Nicholls K, Shankar SP, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18–month results from the randomised phase III ATTRACT study. *J Med Genet.* 2017;54(4):288–296. [CrossRef]
432. Ashe KM, Budman E, Bangari DS, et al. Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease. *Mol Med.* 2015;21(1):389–399. [CrossRef]
433. Domm JM, Wootton SK, Medin JA, West ML. Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene–editing. *Mol Genet Metab.* 2021;134(1–2):117–131. [CrossRef]
434. Seydelmann N, Liu D, Krämer J, et al. High–sensitivity troponin: A clinical blood biomarker for staging cardiomyopathy in Fabry disease. *J Am Heart Assoc.* 2016;5(6):e002839. [CrossRef]
435. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. *N Engl J Med.* 2007;357(21):2153–65. [CrossRef]
436. Mehta D, Lubitz SA, Frankel Z, et al. Cardiac involvement in patients with sarcoidosis: Diagnostic and prognostic value of outpatient testing. *Chest.* 2008;133(6):1426–1435. [CrossRef]
437. Terasaki F, Azuma A, Anzai T, et al. JCS 2016 guideline on diagnosis and treatment of cardiac sarcoidosis– Digest version. *Circ J.* 2019;83(11):2329–2388. [CrossRef]
438. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. *Heart Rhythm.* 2014;11(7):1305–1323. [CrossRef]
439. Slart RHJA, Glaudemans AWJM, Gheysens O, et al. Procedural recommendations of cardiac PET/CT imaging: Standardization in inflammatory–, infective–, infiltrative–, and innervation (4Is)–related cardiovascular diseases: A joint collaboration of the EACVI and the EANM. *Eur J Nucl Med Mol Imaging.* 2021;48(4):1016–1039. [CrossRef]
440. Burstow DJ, Tajik AJ, Bailey KR, DeRemee RA, Taliencio CP. Two–dimensional echocardiographic findings in systemic sarcoidosis. *Am J Cardiol.* 1989;63(7):478–482. [CrossRef]
441. Kandolin R, Lehtonen J, Graner M, et al. Diagnosing isolated cardiac sarcoidosis. *J Intern Med.* 2011;270(5):461–468. [CrossRef]
442. Hatipoglu S, Gardezi SKM, Azzu A, et al. Diagnosis of cardiac sarcoidosis in patients presenting with cardiac arrest or life–threatening arrhythmias. *Heart.* 2023;109(10):748–755. [CrossRef]
443. Rodrigues P, Joshi A, Williams H, et al. Diagnosis and prognosis in sudden cardiac arrest survivors without coronary artery disease: Utility of a clinical approach using cardiac magnetic resonance imaging. *Circ Cardiovasc Imaging.* 2017;10(12):e006709. [CrossRef]
444. Quarta G, Husain SI, Flett AS, et al. Arrhythmogenic right ventricular cardiomyopathy mimics: Role of cardiovascular magnetic resonance. *J Cardiovasc Magn Reson.* 2013;15(1):16. [CrossRef]
445. Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakae S, Kamigaki M, et al. Focal uptake on 18F–fluoro–2–deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. *Eur Heart J.* 2005;26(15):1538–1543. [CrossRef]
446. Varghese M, Smiley D, Bellumkonda L, Rosenfeld LE, Zaret B, Miller EJ. Quantitative interpretation of FDG PET for cardiac sarcoidosis reclassifies visually interpreted exams and potentially impacts downstream interventions. *Sarcoidosis Vasc Diffuse Lung Dis.* 2018;35(4):342–353.
447. Flores RJ, Flaherty KR, Jin Z, Bokhari S. The prognostic value of quantitating and localizing F–18 FDG uptake in cardiac sarcoidosis. *J Nucl Cardiol.* 2020;27(6):2003–2010. [CrossRef]
448. Okumura W, Iwasaki T, Toyama T, et al. Usefulness of fasting 18F–FDG PET in identification of cardiac sarcoidosis. *J Nucl Med.* 2004;45(12):1989–1998.

449. Swart LE, Gomes A, Scholtens AM, Sinha B, Tanis W, Lam MGEH, et al. Improving the diagnostic performance of 18f-fluorodeoxyglucose positron-emission tomography/computed tomography in prosthetic heart valve endocarditis. *Circulation*. 2018;138(14):1412-1427. [CrossRef]
450. Tilke-meier PL, Bourque J, Doukky R, Sanghani R, Weinberg RL. ASNC imaging guidelines for nuclear cardiology procedures: Standardized reporting of nuclear cardiology procedures. *J Nucl Cardiol*. 2017;24(6):2064-2128. [CrossRef]
451. Sciagrà R, Passeri A, Buceri J, et al. Clinical use of quantitative cardiac perfusion PET: Rationale, modalities and possible indications. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM). *Eur J Nucl Med Mol Imaging*. 2016;43(8):1530-1545. [CrossRef]
452. Vita T, Okada DR, Veillet-Chowdhury M, et al. Complementary value of cardiac magnetic resonance imaging and positron emission tomography/computed tomography in the assessment of cardiac sarcoidosis. *Circ Cardiovasc Imaging*. 2018;11(1):e007030. [CrossRef]
453. Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States: A Delphi study. *Chest*. 2012;141(1):154-162. [CrossRef]
454. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society. *Circulation*. 2018;138(13):e210-e271. [CrossRef]
455. Yasuda M, Iwanaga Y, Kato T, et al. Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis. *Open Heart*. 2016;3(2):e000437. [CrossRef]
456. Hulthen E, Agarwal V, Cahill M, et al. Presence of late gadolinium enhancement by cardiac magnetic resonance among patients with suspected cardiac sarcoidosis is associated with adverse cardiovascular prognosis: A systematic review and meta-analysis. *Circ Cardiovasc Imaging*. 2016;9(9):e005001. [CrossRef]
457. Schuller JL, Zipse M, Crawford T, et al. Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis. *J Cardiovasc Electrophysiol*. 2012;23(9):925-929. [CrossRef]
458. Akashi H, Kato TS, Takayama H, et al. Outcome of patients with cardiac sarcoidosis undergoing cardiac transplantation--Single-center retrospective analysis. *J Cardiol*. 2012;60(5):407-410. [CrossRef]
459. Perkel D, Czer LS, Morrissey RP, et al. Heart transplantation for end-stage heart failure due to cardiac sarcoidosis. *Transplant Proc*. 2013;45(6):2384-2346. [CrossRef]
- References 14**
460. Chen S, Chen L, Duru F, Hu S. Heart failure in patients with arrhythmogenic cardiomyopathy. *J Clin Med*. 2021;10(20):4782. [CrossRef]
461. El Hadi H, Freund A, Desch S, Thiele H, Majunke N. Hypertrophic, dilated, and arrhythmogenic cardiomyopathy: Where are we? *Biomedicines*. 2023;11(2):524. [CrossRef]
462. Marcus FI, Fontaine GH, Guiraudon G, et al. Right ventricular dysplasia: A report of 24 adult cases. *Circulation*. 1982;65(2):384-398. [CrossRef]
463. McKenna WJ, Thiene G, Nava A, et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. *Br Heart J*. 1994;71(3):215-218. [CrossRef]
464. Basso C, Thiene G, Corrado D, Angelini A, Nava A, Valente M. Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy, or myocarditis? *Circulation*. 1996;94(5):983-991. [CrossRef]
465. Cipriani A, Bauce B, De Lazzari M, et al. Arrhythmogenic right ventricular cardiomyopathy: Characterization of left ventricular phenotype and differential diagnosis with dilated cardiomyopathy. *J Am Heart Assoc*. 2020;9(5):e014628. [CrossRef]
466. Pérez-Riera AR, Barbosa-Barros R, Daminello-Raimundo R, et al. Epsilon wave: A review of historical aspects. *Indian Pacing Electrophysiol J*. 2019;19(2):63-67. [CrossRef]
467. Haugaa KH, Basso C, Badano LP, et al. Comprehensive multi-modality imaging approach in arrhythmogenic cardiomyopathy-An expert consensus document of the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*. 2017;18(3):237-253. [CrossRef]
468. Gandjbakhch E, Redheuil A, Pousset F, Charron P, Frank R. Clinical diagnosis, imaging, and genetics of arrhythmogenic right ventricular cardiomyopathy/dysplasia: JACC state-of-the-art review. *J Am Coll Cardiol*. 2018;72(7):784-804. [CrossRef]
469. Basso C, Thiene G. Adipositas cordis, fatty infiltration of the right ventricle, and arrhythmogenic right ventricular cardiomyopathy. Just a matter of fat? *Cardiovasc Pathol*. 2005;14(1):37-41. [CrossRef]
470. Paul M, Meyborg M, Boknik P, et al. Autonomic dysfunction in patients with arrhythmogenic right ventricular cardiomyopathy: biochemical evidence of altered signaling pathways. *Pacing Clin Electrophysiol*. 2014;37(2):173-178. [CrossRef]
471. Pilichou K, Thiene G, Bauce B, et al. Arrhythmogenic cardiomyopathy. *Orphanet J Rare Dis*. 2016;11:33. [CrossRef]
472. Corrado D, Basso C. Arrhythmogenic left ventricular cardiomyopathy. *Heart*. 2022;108(9):733-743. [CrossRef]
473. McNally E, MacLeod H, Dellefave-Castillo L. Arrhythmogenic right ventricular cardiomyopathy overview. In: Adam MP, Feldman J, Mirzaa GM, et al, eds. *GeneReviews [Internet]*. Seattle: Seattle WA; 2005;1993-2024.
474. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: Proposed modification of the Task Force Criteria. *Eur Heart J*. 2010;31(7):806-814. [CrossRef]
475. Corrado D, Perazzolo Marra M, Zorzi A, et al. Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria. *Int J Cardiol*. 2020;319:106-114. [CrossRef]
476. Perazzolo Marra M, Cipriani A, Rizzo S, et al. myocardial tissue characterization in arrhythmogenic cardiomyopathy: Comparison between endomyocardial biopsy and cardiac magnetic resonance. *JACC Cardiovasc Imaging*. 2021;14(8):1675-1678. [CrossRef]
477. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: A report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. *J Am Soc Echocardiogr*. 2010;23(7):685-788. [CrossRef]
478. Corrado D, Cipriani A, De Lazzari M, Perazzolo Marra M. Right ventricular dilatation in arrhythmogenic right ventricular cardiomyopathy: Need for a revision of the 2010 International Task Force criteria. *Eur Heart J*. 2020;41(14):1452-1453. [CrossRef]
479. Corrado D, Zorzi A, Cipriani A, et al. Evolving diagnostic criteria for arrhythmogenic cardiomyopathy. *J Am Heart Assoc*. 2021;10(18):e021987. [CrossRef]
480. Petersen SE, Khanji MY, Plein S, Lancellotti P, Bucciarelli-Ducci C. European Association of Cardiovascular Imaging expert consensus paper: A comprehensive review of cardiovascular magnetic resonance normal values of cardiac chamber size and aortic root in adults and recommendations for grading severity. *Eur Heart J Cardiovasc Imaging*. 2019;20(12):1321-1331. [CrossRef]
481. D'Ascenzi F, Anselmi F, Piu P, et al. Cardiac magnetic resonance normal reference values of biventricular size and function in male athlete's heart. *JACC Cardiovasc Imaging*. 2019;12(9):1755-1765. [CrossRef]
482. Corrado D, van Tintelen PJ, McKenna WJ, et al. Arrhythmogenic right ventricular cardiomyopathy: Evaluation of the current diagnostic criteria and differential diagnosis. *Eur Heart J*. 2020;41(14):1414-1429. [CrossRef]
483. Writing group; Document reading group; EACVI Reviewers: This document was reviewed by members of the EACVI Scientific Documents Committee for 2014-2016 and 2016-2018. A joint

- procedural position statement on imaging in cardiac sarcoidosis: From the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. *Eur Heart J Cardiovasc Imaging*. 2017;18(10):1073-1089. [CrossRef]
484. Protonotarios A, Wicks E, Ashworth M, et al. Prevalence of ¹⁸F-fluorodeoxyglucose positron emission tomography abnormalities in patients with arrhythmogenic right ventricular cardiomyopathy. *Int J Cardiol*. 2019;284:99-104. [CrossRef]
485. Sarvari SI, Haugaa KH, Anfinson OG, et al. Right ventricular mechanical dispersion is related to malignant arrhythmias: a study of patients with arrhythmogenic right ventricular cardiomyopathy and subclinical right ventricular dysfunction. *Eur Heart J*. 2011;32(9):1089-96. [CrossRef]
486. Teske AJ, Cox MG, De Boeck BW, Doevendans PA, Hauer RN, Cramer MJ. Echocardiographic tissue deformation imaging quantifies abnormal regional right ventricular function in arrhythmogenic right ventricular dysplasia/cardiomyopathy. *J Am Soc Echocardiogr*. 2009;22(8):920-927. [CrossRef]
487. Haugaa KH, Haland TF, Leren IS, Saberniak J, Edvardsen T. Arrhythmogenic right ventricular cardiomyopathy, clinical manifestations, and diagnosis. *Europace*. 2016;18(7):965-972. [CrossRef]
488. Lopez-Ayala JM, Pastor-Quirante F, Gonzalez-Carrillo J, et al. Genetics of myocarditis in arrhythmogenic right ventricular dysplasia. *Heart Rhythm*. 2015;12(4):766-773. [CrossRef]
489. Molitor N, Duru F. Arrhythmogenic right ventricular cardiomyopathy and differential diagnosis with diseases mimicking its phenotypes. *J Clin Med*. 2022;11(5):1230. [CrossRef]
490. Laredo M, Duthoit G, Gandjbakhch E, Redheuil A, Hébert JL. Total pericardium agenesis mistaken for arrhythmogenic right ventricular cardiomyopathy. *Eur Heart J Cardiovasc Imaging*. 2018;19(1):120. [CrossRef]
491. Bariani R, Cipriani A, Rizzo S, et al. 'Hot phase' clinical presentation in arrhythmogenic cardiomyopathy. *Europace*. 2021;23(6):907-917. [CrossRef]
492. Mattesi G, Zorzi A, Corrado D, Cipriani A. Natural history of arrhythmogenic cardiomyopathy. *J Clin Med*. 2020;9(3):878. [CrossRef]
493. Miles C, Finocchiaro G, Papadakis M, et al. Sudden death and left ventricular involvement in arrhythmogenic cardiomyopathy. *Circulation*. 2019;139(15):1786-1797. [CrossRef]
494. Sen-Chowdhry S, Syrris P, Prasad SK, et al. Left-dominant arrhythmogenic cardiomyopathy: An under-recognized clinical entity. *J Am Coll Cardiol*. 2008;52(25):2175-2187. [CrossRef]
495. Zorzi A, Perazzolo Marra M, Rigato I, et al. Nonischemic left ventricular scar as a substrate of life-threatening ventricular arrhythmias and sudden cardiac death in competitive athletes. *Circ Arrhythm Electrophysiol*. 2016;9(7):e004229. [CrossRef]
496. Sephekrhouy S, Gho JMIH, van Es R, et al. Distinct fibrosis pattern in desmosomal and phospholamban mutation carriers in hereditary cardiomyopathies. *Heart Rhythm*. 2017;14(7):1024-1032. [CrossRef]
497. Corrado D, Wichter T, Link MS, et al. treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: An international task force consensus statement. *Circulation*. 2015;132(5):441-453. [CrossRef]
498. Cadrin-Tourigny J, Bosman LP, Nozza A, et al. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. *Eur Heart J*. 2019;40(23):1850-1858. [CrossRef]
499. Protonotarios A, Bariani R, Cappelletto C, et al. Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator. *Eur Heart J*. 2022;43(32):3053-3067. [CrossRef]
500. Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardia-induced cardiomyopathy: A review of animal models and clinical studies. *J Am Coll Cardiol*. 1997;29(4):709-715. [CrossRef]
501. Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: A reversible form of left ventricular dysfunction. *Am J Cardiol*. 1986;57(8):563-570. [CrossRef]
502. Whipple GH, Sheffield LT, Woodman EG. Reversible congestive heart failure due to chronic rapid stimulation of the normal heart. *Pro N Engl Cardiovasc Soc*. 1962;20:39-40.
503. Ulus T, AlA. Taşikardi ve pacemaker ile tetiklenen kardiyomiyopati. In: Çavuşoğlu Y, ed. *Kalp yetersizliğine yol açan nadir kardiyomiyopatiler: Tanı ve tedavi yaklaşımları*. 1st ed. Ankara: Türkiye Klinikleri; 2020:40-46.
504. Gopinathannair R, Etheridge SP, Marchlinski FE, Spinale FG, Lakkireddy D, Olshansky B. Arrhythmia-Induced Cardiomyopathies: Mechanisms, Recognition, and Management. *J Am Coll Cardiol*. 2015;66(15):1714-1728. [CrossRef]
505. Kjekshus J. Arrhythmias and mortality in congestive heart failure. *Am J Cardiol*. 1990;65(19):421-481. [CrossRef]
506. Coleman HN 3rd, Taylor RR, Pool PE, et al. Congestive heart failure following chronic tachycardia. *Am Heart J*. 1971;81(6):790-798. [CrossRef]
507. Umana E, Solares CA, Alpert MA. Tachycardia-induced cardiomyopathy. *Am J Med*. 2003;114(1):51-55. [CrossRef]
508. Della Rocca DG, Santini L, Forleo GB, et al. Novel perspectives on arrhythmia-induced cardiomyopathy: Pathophysiology, clinical manifestations and an update on invasive management strategies. *Cardiol Rev*. 2015;23:135-141. [CrossRef]
509. Ulus T, Okyay K, Kabul HK, et al. Turkish Society of Cardiology consensus paper on management of arrhythmia-induced cardiomyopathy. *Anatol J Cardiol*. 2019;21(2):98-106. [CrossRef]
510. Huizar JF, Ellenbogen KA, Tan AY, Kaszala K. Arrhythmia-induced cardiomyopathy: JACC state-of-the-art review. *J Am Coll Cardiol*. 2019;73(18):2328-2344. [CrossRef]
511. Yokokawa M, Good E, Crawford T, et al. Recovery from left ventricular dysfunction after ablation of frequent premature ventricular complexes. *Heart Rhythm*. 2013;10(2):172-175. [CrossRef]
512. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. *Am J Cardiol*. 2003;91(6A):2D-8D. [CrossRef]
513. Riegger AJ, Liebau G. The renin-angiotensin-aldosterone system, antidiuretic hormone and sympathetic nerve activity in an experimental model of congestive heart failure in the dog. *Clin Sci (Lond)*. 1982;62(5):465-469. [CrossRef]
514. Redfield MM, Aarhus LL, Wright RS, Burnett JC Jr. Cardioresenal and neurohumoral function in a canine model of early left ventricular dysfunction. *Circulation*. 1993;87(6):2016-2022. [CrossRef]
515. Moe GW, Stopps TP, Howard RJ, Armstrong PW. Early recovery from heart failure: Insights into the pathogenesis of experimental chronic pacing-induced heart failure. *J Lab Clin Med*. 1988;112(4):426-432.
516. Sugumar H, Prabhu S, Voskoboinik A, Kistler PM. Arrhythmia induced cardiomyopathy. *J Arrhythm*. 2018;34(4):376-383. [CrossRef]
517. Kim DY, Kim SH, Ryu KH. Tachycardia induced cardiomyopathy. *Korean Circ J*. 2019;49(9):808-817. [CrossRef]
518. Martin CA, Lambiase PD. Pathophysiology, diagnosis and treatment of tachycardiomyopathy. *Heart*. 2017;103(19):1543-1552. [CrossRef]
519. Damiano RJ Jr, Tripp HF Jr, Asano T, Small KW, Jones RH, Lowe JE. Left ventricular dysfunction and dilatation resulting from chronic supraventricular tachycardia. *J Thorac Cardiovasc Surg*. 1987;94(1):135-143. [CrossRef]
520. Ellis ER, Josephson ME. What about tachycardia-induced cardiomyopathy? *Arrhythm Electrophysiol Rev*. 2013;2(2):82-90. [CrossRef]
521. Gupta S, Figueredo VM. Tachycardia mediated cardiomyopathy: Pathophysiology, mechanisms, clinical features and management. *Int J Cardiol*. 2014;172(1):40-46. [CrossRef]
522. Krapp M, Gembruch U, Baumann P. Venous blood flow pattern suggesting tachycardia-induced 'cardiomyopathy' in the fetus. *Ultrasound Obstet Gynecol*. 1997;10(1):32-40. [CrossRef]
523. Stegmann C, Hindricks G. Atrial fibrillation in heart failure-diagnostic, therapeutic, and prognostic relevance. *Curr Heart Fail Rep*. 2019;16(4):108-115. [CrossRef]

524. Kirchhof P, Benussi S, Kotecha D, et al.; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J*. 2016;37(38):2893-2962. [CrossRef]
525. Huffman C, Wagman G, Fudim M, Zolty R, Vittorio T. Reversible cardiomyopathies—a review. *Transplant Proc*. 2010;42(9):3673-3678. [CrossRef]
526. Hasdemir C, Ulucan C, Yavuzgil O, et al. Tachycardia-induced cardiomyopathy in patients with idiopathic ventricular arrhythmias: The incidence, clinical and electrophysiologic characteristics, and the predictors. *J Cardiovasc Electrophysiol*. 2011;22(6):663-668. [CrossRef]
527. Dhawan R, Gopinathannair R. Arrhythmia-induced cardiomyopathy: Prevalent, under-recognized, reversible. *J Atr Fibrillation*. 2017;10(3):1776. [CrossRef]
528. Nia AM, Gassanov N, Dahlem KM, et al. Diagnostic accuracy of NT-proBNP ratio (BNP-R) for early diagnosis of tachycardia-mediated cardiomyopathy: A pilot study. *Clin Res Cardiol*. 2011;100(10):887-896. [CrossRef]
529. Mueller KAL, Heinzmann D, Klingel K, et al. Histopathological and immunological characteristics of tachycardia-induced cardiomyopathy. *J Am Coll Cardiol*. 2017;69(17):2160-2172. [CrossRef]
530. Jeong YH, Choi KJ, Song JM, et al. Diagnostic approach and treatment strategy in tachycardia-induced cardiomyopathy. *Clin Cardiol*. 2008;31(4):172-178. [CrossRef]
531. Fujino T, Yamashita T, Suzuki S, et al. Characteristics of congestive heart failure accompanied by atrial fibrillation with special reference to tachycardia-induced cardiomyopathy. *Circ J*. 2007;71(6):936-940. [CrossRef]
532. Okada A, Nakajima I, Morita Y, et al. Diagnostic value of right ventricular dysfunction in tachycardia-induced cardiomyopathy using cardiac magnetic resonance imaging. *Circ J*. 2016;80(10):2141-2148. [CrossRef]
533. Geyer H, Caracciolo G, Abe H, et al. Assessment of myocardial mechanics using speckle tracking echocardiography: Fundamentals and clinical applications. *J Am Soc Echocardiogr*. 2010;23(4):351-455. [CrossRef]
534. Hasdemir C, Yuksel A, Camli D, et al. Late gadolinium enhancement CMR in patients with tachycardia-induced cardiomyopathy caused by idiopathic ventricular arrhythmias. *Pacing Clin Electrophysiol*. 2012;35(4):465-470. [CrossRef]
535. Grewal J, Majdalany D, Syed I, Pellikka P, Warnes CA. Three-dimensional echocardiographic assessment of right ventricular volume and function in adult patients with congenital heart disease: Comparison with magnetic resonance imaging. *J Am Soc Echocardiogr*. 2010;23(2):127-133. [CrossRef]
536. Kalogeropoulos AP, Fonarow GC, Georgiopoulos V, et al. Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction. *JAMA Cardiol*. 2016;1(5):510-518. [CrossRef]
537. McDonagh TA, Metra M, Adamo M, et al; ESC Scientific Document Group. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*. 2021;42(36):3599-3726. [CrossRef]
538. Hindricks G, Potpara T, Dagres N, et al; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J*. 2021;42(5):373-498. [CrossRef]
539. Chung MK, Shemanski L, Sherman DG, et al; AFFIRM Investigators. Functional status in rate- versus rhythm-control strategies for atrial fibrillation: Results of the atrial fibrillation follow-up investigation of rhythm Management (AFFIRM) functional status substudy. *J Am Coll Cardiol*. 2005;46(10):1891-1899. [CrossRef]
540. Torp-Pedersen C, Møller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish investigations of arrhythmia and mortality on dofetilide study group. *N Engl J Med*. 1999;341(12):857-865. [CrossRef]
541. Roy D, Talajic M, Nattel S, et al; Atrial fibrillation and congestive heart failure investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. *N Engl J Med*. 2008;358(25):2667-2677. [CrossRef]
542. Latchamsetty R, Bogun F. Premature ventricular complexes and premature ventricular complex induced cardiomyopathy. *Curr Probl Cardiol*. 2015;40(9):379-422. [CrossRef]
543. Panizo JG, Barra S, Mellor G, Heck P, Agarwal S. Premature ventricular complex-induced cardiomyopathy. *Arrhythm Electrophysiol Rev*. 2018;7(2):128-134. [CrossRef]
544. Sadron Blaye-Felice M, Hamon D, Sacher F, et al. Premature ventricular contraction-induced cardiomyopathy: Related clinical and electrophysiologic parameters. *Heart Rhythm*. 2016;13(1):103-110. [CrossRef]
545. Gorenek B, Fisher JD, Kudaiberdieva G, et al. Premature ventricular complexes: Diagnostic and therapeutic considerations in clinical practice: A state-of-the-art review by the American College of Cardiology Electrophysiology Council. *J Interv Card Electrophysiol*. 2020;57(1):5-26. [CrossRef]
546. Khurshid S, Epstein AE, Verdino RJ, et al. Incidence and predictors of right ventricular pacing-induced cardiomyopathy. *Heart Rhythm*. 2014;11(9):1619-1625. [CrossRef]
547. Kim JH, Kang KW, Chin JY, Kim TS, Park JH, Choi YJ. Major determinant of the occurrence of pacing-induced cardiomyopathy in complete atrioventricular block: A multicentre, retrospective analysis over a 15-year period in South Korea. *BMJ Open*. 2018;8(2):e019048. [CrossRef]
548. Erbel R, Aboyans V, Boileau C, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The task force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). *Eur Heart J*. 2014;35(41):2873-2926. [CrossRef]
549. Panda S, Sahoo SC, Sharma SK. A systemic review hypokinetic nondilated cardiomyopathy, an under diagnosed, under estimated subcategory of dilated cardiomyopathy: Needs redressal. *J Cardiovasc Dis Res*. 2021;12(3):970-981.
550. Altschul E, Remy-Jardin M, Machnicki S, et al. Imaging of pulmonary hypertension: Pictorial essay. *Chest*. 2019;156(2):211-227. [CrossRef]
551. Gluecker T, Capasso P, Schnyder P et al. Clinical and radiologic features of pulmonary edema. *Radiographics*. 1999;19(6):1507-1533. [CrossRef]
552. Pinamonti B, Abate E, De Luca A, Finocchiaro G, Korcova R. Role of cardiac imaging: Echocardiography. Accessed April 2, 2024. <https://www.openaccessrepository.it/record/31190>.
553. Dziewięcka E, Winiarczyk M, Wiśniowska-Śmiątek S, et al. Comparison of clinical course and outcomes between dilated and hypokinetic non-dilated cardiomyopathy. *Cardiology*. 2023;148(5):395-401. [CrossRef]
554. Eda Y, Nabeta T, Iikura S, et al. Non-dilated left ventricular cardiomyopathy vs. dilated cardiomyopathy: Clinical background and outcomes. Accessed April 2, 2024. <https://onlinelibrary.wiley.com/doi/10.1002/ehf2.14711>. [CrossRef]
555. Cioffi G, Tarantini L, De Feo S, et al. Dilated versus nondilated cardiomyopathy in the elderly population treated with guideline-based medical therapy for systolic chronic heart failure. *J Card Fail*. 2004;10(6):481-489. [CrossRef]
556. Lancellotti P, Nkomo VT, Badano LP, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: A report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. *Eur Heart J Cardiovasc Imaging*. 2013;14(8):721-740. [CrossRef]
557. Murtaza G, Virk HUH, Khalid M, et al. Role of speckle tracking echocardiography in dilated cardiomyopathy: A review. *Cureus*. 2017;9(6):e1372. [CrossRef]

558. Mombeini H, Parsaee M, Amin A. Speckle tracking echocardiography in hypokinetic non-dilated cardiomyopathy: Comparison with dilated cardiomyopathy. *ESC Heart Fail.* 2020;7(4):1909-1916. [\[CrossRef\]](#)
559. Haugaa KH, Goebel B, Dahlslett T, et al. Risk assessment of ventricular arrhythmias in patients with nonischemic dilated cardiomyopathy by strain echocardiography. *J Am Soc Echocardiogr.* 2012;25(6):667-673. [\[CrossRef\]](#)
560. Knuuti J, Wijns W, Saraste A, et al.; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J.* 2020;41(3):407-477. Erratum in: *Eur Heart J.* 2020;41(44):4242. [\[CrossRef\]](#)
561. Banerjee A, Newman DR, Van den Bruel A, Heneghan C. Diagnostic accuracy of exercise stress testing for coronary artery disease: a systematic review and meta-analysis of prospective studies. *Int J Clin Pract.* 2012;66(5):477-492. [\[CrossRef\]](#)
562. Mewton N, Liu CY, Croisille P, Bluemke D, Lima JA. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. *J Am Coll Cardiol.* 2011;57(8):891-903. [\[CrossRef\]](#)
563. Kuruville S, Adenaw N, Katwal AB, Lipinski MJ, Kramer CM, Salerno M. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: A systematic review and meta-analysis. *Circ Cardiovasc Imaging.* 2014;7(2):250-258. [\[CrossRef\]](#)
564. Start RHJA, Glaudemans AWJM, Lancellotti P, Hyafil F, Blankstein R, Schwartz RG, et al. A joint procedural position statement on imaging in cardiac sarcoidosis: From the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. *J Nucl Cardiol.* 2018;25(1):298-319. [\[CrossRef\]](#)
565. Frazier OH, Rose EA, Macmanus Q, et al. Multicenter clinical evaluation of the HeartMate 1000 IP left ventricular assist device. *Ann Thorac Surg.* 1992;53(6):1080-1090. [\[CrossRef\]](#)
566. Rose EA, Gelijns AC, Moskowitz AJ, et al.; Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. *N Engl J Med.* 2001;345(20):1435-1443. [\[CrossRef\]](#)
567. Stewart GC, Givertz MM. Mechanical circulatory support for advanced heart failure: patients and technology in evolution. *Circulation.* 2012;125(10):1304-1315. [\[CrossRef\]](#)
568. Saeed D, Feldman D, Banayosy AE, et al. The 2023 International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support: A 10- Year Update. *J Heart Lung Transplant.* 2023;42(7):e1-e222.
569. Goodman D, Stulak J, Rosenbaum AN. Left ventricular assist devices: A historical perspective at the intersection of medicine and engineering. *Artif Organs.* 2022;46(12):2343-2360. [\[CrossRef\]](#)
570. Pagani FD, Miller LW, Russell SD, et al.; HeartMate II Investigators. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. *J Am Coll Cardiol.* 2009;54(4):312-321. [\[CrossRef\]](#)
571. Mehra MR, Uriel N, Naka Y, et al.; MOMENTUM 3 Investigators. A Fully Magnetically Levitated Left Ventricular Assist Device - Final Report. *N Engl J Med.* 2019;380(17):1618-1627. [\[CrossRef\]](#)
572. Stainback RF, Estep JD, Agler DA, et al.; American Society of Echocardiography. Echocardiography in the Management of Patients with Left Ventricular Assist Devices: Recommendations from the American Society of Echocardiography. *J Am Soc Echocardiogr.* 2015;28(8):853-909. [\[CrossRef\]](#)
573. Ammar KA, Umland MM, Kramer C, et al. The ABCs of left ventricular assist device echocardiography: a systematic approach. *Eur Heart J Cardiovasc Imaging.* 2012;13(11):885-899. [\[CrossRef\]](#)
574. Gardin JM, Adams DB, Douglas PS, et al.; American Society of Echocardiography. Recommendations for a standardized report for adult transthoracic echocardiography: a report from the American Society of Echocardiography's Nomenclature and Standards Committee and Task Force for a Standardized Echocardiography Report. *J Am Soc Echocardiogr.* 2002;15(3):275-290. [\[CrossRef\]](#)
575. Mor-Avi V, Lang RM, Badano LP, et al. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. *Eur J Echocardiogr.* 2011;12(3):167-205. [\[CrossRef\]](#)
576. Porter TR, Abdelmoneim S, Belcik JT, et al. Guidelines for the cardiac sonographer in the performance of contrast echocardiography: a focused update from the American Society of Echocardiography. *J Am Soc Echocardiogr.* 2014;27(8):797-810. [\[CrossRef\]](#)
577. Topilsky Y, Oh JK, Shah DK, et al. Echocardiographic predictors of adverse outcomes after continuous left ventricular assist device implantation. *JACC Cardiovasc Imaging.* 2011;4(3):211-222. [\[CrossRef\]](#)
578. Fitzpatrick JR 3rd, Frederick JR, Hsu VM, et al. Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support. *J Heart Lung Transplant.* 2008;27(12):1286-1292. [\[CrossRef\]](#)
579. Neyer J, Arsanjani R, Moriguchi J, Siegel R, Kobashigawa J. Echocardiographic parameters associated with right ventricular failure after left ventricular assist device: A review. *J Heart Lung Transplant.* 2016;35(3):283-293. [\[CrossRef\]](#)
580. Vivo RP, Cordero-Reyes AM, Qamar U, et al. Increased right-to-left ventricle diameter ratio is a strong predictor of right ventricular failure after left ventricular assist device. *J Heart Lung Transplant.* 2013;32(8):792-799. [\[CrossRef\]](#)
581. Tamborini G, Pepi M, Galli CA, et al. Feasibility and accuracy of a routine echocardiographic assessment of right ventricular function. *Int J Cardiol.* 2007;115(1):86-89. [\[CrossRef\]](#)
582. Puwanant S, Hamilton KK, Klodell CT, et al. Tricuspid annular motion as a predictor of severe right ventricular failure after left ventricular assist device implantation. *J Heart Lung Transplant.* 2008;27(10):1102-1107. [\[CrossRef\]](#)
583. Grant AD, Smedira NG, Starling RC, Marwick TH. Independent and incremental role of quantitative right ventricular evaluation for the prediction of right ventricular failure after left ventricular assist device implantation. *J Am Coll Cardiol.* 2012;60(6):521-528. [\[CrossRef\]](#)
584. Imamura T, Kinugawa K, Kato N, et al. Late-onset right ventricular failure in patients with preoperative small left ventricle after implantation of continuous flow left ventricular assist device. *Circulation.* 2014;78(3):625-633. [\[CrossRef\]](#)
585. Kiernan MS, French AL, DeNofrio D, et al. Preoperative three-dimensional echocardiography to assess risk of right ventricular failure after left ventricular assist device surgery. *J Card Fail.* 2015;21(3):189-197. [\[CrossRef\]](#)
586. Potapov EV, Stepanenko A, Dandel M, et al. Tricuspid incompetence and geometry of the right ventricle as predictors of right ventricular function after implantation of a left ventricular assist device. *J Heart Lung Transplant.* 2008;27(12):1275-1281. [\[CrossRef\]](#)
587. Zoghbi WA, Chambers JB, Dumesnil JG, et al.; American Society of Echocardiography's Guidelines and Standards Committee; Task Force on Prosthetic Valves; American College of Cardiology Cardiovascular Imaging Committee; Cardiac Imaging Committee of the American Heart Association; European Association of Echocardiography; European Society of Cardiology; Japanese Society of Echocardiography; American College of Cardiology Foundation; American Heart Association; European Association of Echocardiography; European Society of Cardiology; Japanese Society of Echocardiography; Canadian Society of Echocardiography. Recommendations for evaluation of prosthetic valves with echocardiography and doppler ultrasound: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Task Force on Prosthetic Valves, developed in conjunction with the American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the American Heart Association, the European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography and the Canadian Society of Echocardiography, endorsed by the American

- College of Cardiology Foundation, American Heart Association, European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography, and Canadian Society of Echocardiography. *J Am Soc Echocardiogr*. 2009;22(9):975-1014; quiz 1082-1084.
588. Lancellotti P, Tribouilloy C, Hagendorff A, et al.; Scientific Document Committee of the European Association of Cardiovascular Imaging. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*. 2013;14(7):611-644. [CrossRef]
589. Park SJ, Liao KK, Segurola R, Madhu KP, Miller LW. Management of aortic insufficiency in patients with left ventricular assist devices: a simple coaptation stitch method (Park's stitch). *J Thorac Cardiovasc Surg*. 2004;127(1):264-266. [CrossRef]
590. Kilger E, Strom C, Frey L, et al. Intermittent atrial level right-to-left shunt with temporary hypoxemia in a patient during support with a left ventricular assist device. *Acta Anaesthesiol Scand*. 2000;44(1):125-127. [CrossRef]
591. Feldman D, Pamboukian SV, Teuteberg JJ, et al.; International Society for Heart and Lung Transplantation. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. *J Heart Lung Transplant*. 2013;32(2):157-187. [CrossRef]
592. Estep JD, Stainback RF, Little SH, Torre G, Zoghbi WA. The role of echocardiography and other imaging modalities in patients with left ventricular assist devices. *JACC Cardiovasc Imaging*. 2010;3(10):1049-1064. [CrossRef]
593. Estep JD, Chang SM, Bhimaraj A, Torre-Amione G, Zoghbi WA, Nagueh SF. Imaging for ventricular function and myocardial recovery on nonpulsatile ventricular assist devices. *Circulation*. 2012;125(18):2265-2277. [CrossRef]
594. Hatano M, Kinugawa K, Shiga T, et al. Less frequent opening of the aortic valve and a continuous flow pump are risk factors for postoperative onset of aortic insufficiency in patients with a left ventricular assist device. *Circulation*. 2011;75(5):1147-1155. [CrossRef]
595. Hetzer R, Müller JH, Weng Y, Meyer R, Dandel M. Bridging-to-recovery. *Ann Thorac Surg*. 2001;71(3 Suppl):S109-S113; discussion S114-S115. [CrossRef]
596. Topilsky Y, Oh JK, Atchison FW, et al. Echocardiographic findings in stable outpatients with properly functioning HeartMate II left ventricular assist devices. *J Am Soc Echocardiogr*. 2011;24(2):157-169. [CrossRef]
597. Cowger J, Pagani FD, Haft JW, Romano MA, Aaronson KD, Koliás TJ. The development of aortic insufficiency in left ventricular assist device-supported patients. *Circ Heart Fail*. 2010;3(6):668-674. [CrossRef]
598. Pak SW, Uriel N, Takayama H, et al. Prevalence of de novo aortic insufficiency during long-term support with left ventricular assist devices. *J Heart Lung Transplant*. 2010;29(10):1172-1176. [CrossRef]
599. Grinstein J, Kruse E, Sayer G, et al. Accurate Quantification Methods for Aortic Insufficiency Severity in Patients With LVAD: Role of Diastolic Flow Acceleration and Systolic-to-Diastolic Peak Velocity Ratio of Outflow Cannula. *JACC Cardiovasc Imaging*. 2016;9(6):641-651. [CrossRef]
600. Catena E, Milazzo F, Montorsi E, et al. Left ventricular support by axial flow pump: the echocardiographic approach to device malfunction. *J Am Soc Echocardiogr*. 2005;18(12):1422. [CrossRef]
601. Hamilton A, Huang SL, Warnick D, et al. Left ventricular thrombus enhancement after intravenous injection of echogenic immunoliposomes: studies in a new experimental model. *Circulation*. 2002;105(23):2772-2778. [CrossRef]
602. Edvardsen T, Asch FM, Davidson B, et al. Non-invasive imaging in coronary syndromes: Recommendations of the European Association of Cardiovascular Imaging and the American Society of Echocardiography, in collaboration with the American Society of Nuclear Cardiology, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. *Eur Heart J Cardiovasc Imaging*. 2022;23(2):e6-e33. [CrossRef]
603. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J*. 2020;41(3):407-477. [CrossRef]
604. Schuster A, Morton G, Chiribiri A, Perera D, Vanoverschelde JL, Nagel E. Imaging in the management of ischemic cardiomyopathy: Special focus on magnetic resonance. *J Am Coll Cardiol*. 2012;59(4):359-370. [CrossRef]
605. Muscogiuri G, Guglielmo M, Serra A, et al. Multimodality Imaging in Ischemic Chronic Cardiomyopathy. *J Imaging*. 2022;8(2):35. [CrossRef]
606. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. *Circulation*. 2022;145(18):e895-e1032. [CrossRef]
607. Solomon SD, Skali H, Anavekar NS, et al. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. *Circulation*. 2005;111(25):3411-3419. [CrossRef]
608. Dorosz JL, Lezotte DC, Weitzenkamp DA, Allen LA, Salcedo EE. Performance of 3-dimensional echocardiography in measuring left ventricular volumes and ejection fraction: A systematic review and meta-analysis. *J Am Coll Cardiol*. 2012;59(20):1799-1808. [CrossRef]
609. Briceno N, Schuster A, Lumley M, Perera D. Ischaemic cardiomyopathy: Pathophysiology, assessment and the role of revascularisation. *Heart*. 2016;102(5):397-406. [CrossRef]
610. Biering-Sørensen T, Olsen FJ, Storm K, et al. Prognostic value of tissue Doppler imaging for predicting ventricular arrhythmias and cardiovascular mortality in ischaemic cardiomyopathy. *Eur Heart J Cardiovasc Imaging*. 2016;17(7):722-731. [CrossRef]
611. Chelliah RK, Hickman M, Kinsey C, Burden L, Senior R. Myocardial contrast echocardiography versus single photon emission computed tomography for assessment of hibernating myocardium in ischemic cardiomyopathy: Preliminary qualitative and quantitative results. *J Am Soc Echocardiogr*. 2010;23(8):840-847. [CrossRef]
612. Brady B, King G, Murphy RT, Walsh D. Myocardial strain: A clinical review. *Ir J Med Sci*. 2023;192(4):1649-1656. [CrossRef]
613. Collier P, Phelan D, Klein A. A test in context: Myocardial strain measured by speckle-tracking echocardiography. *J Am Coll Cardiol*. 2017;69(8):1043-1056. [CrossRef]
614. Biering-Sørensen T, Hoffmann S, Mogelvang R, et al. Myocardial strain analysis by 2-dimensional speckle tracking echocardiography improves diagnostics of coronary artery stenosis in stable angina pectoris. *Circ Cardiovasc Imaging*. 2014;7(1):58-65. [CrossRef]
615. Bertini M, Ng AC, Antoni ML, et al. Global longitudinal strain predicts long-term survival in patients with chronic ischemic cardiomyopathy. *Circ Cardiovasc Imaging*. 2012;5(3):383-391. [CrossRef]
616. Yingchoncharoen T, Agarwal S, Popović ZB, Marwick TH. Normal ranges of left ventricular strain: A meta-analysis. *J Am Soc Echocardiogr*. 2013;26(2):185-191. [CrossRef]
617. Hamada S, Schroeder J, Hoffmann R, et al. Prediction of outcomes in patients with chronic ischemic cardiomyopathy by layer-specific strain echocardiography: A proof of concept. *J Am Soc Echocardiogr*. 2016;29(5):412-420. [CrossRef]
618. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the management of patients with chronic coronary disease: A report of the American Heart Association/American College of Cardiology Joint Committee on clinical practice guidelines. *Circulation*. 2023;148(9):e9-e119. [CrossRef]
619. Ciampi Q, Zagatina A, Cortigiani L, et al. Prognostic value of stress echocardiography assessed by the ABCDE protocol. *Eur Heart J*. 2021;42(37):3869-3878. [CrossRef]
620. Pellikka PA, Arruda-Olson A, Chaudhry FA, et al. Guidelines for performance, interpretation, and application of stress echocardiography in ischemic heart disease: From the American Society of Echocardiography. *J Am Soc Echocardiogr*. 2020;33(1):1-41.e8. [CrossRef]

621. Picano E, Pierard L, Peteiro J, et al. The clinical use of stress echocardiography in chronic coronary syndromes and beyond coronary artery disease: A clinical consensus statement from the European Association of Cardiovascular Imaging of the ESC. *Eur Heart J Cardiovasc Imaging*. 2024;25(2):e65-e90. [CrossRef]
622. Coats AJS, Anker SD, Baumbach A, et al. The management of secondary mitral regurgitation in patients with heart failure: A joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. *Eur Heart J*. 2021;42(13):1254-1269. [CrossRef]
623. Bax JJ, Di Carli M, Narula J, Delgado V. Multimodality imaging in ischaemic heart failure. *Lancet*. 2019;393(10175):1056-1070. [CrossRef]
624. Salavati A, Radmanesh F, Heidari K, Dwamena BA, Kelly AM, Cronin P. Dual-radionuclide computed tomography angiography for diagnosis and assessment of coronary artery disease: Systematic review and meta-analysis. *J Cardiovasc Comput Tomogr*. 2012;6(2):78-90. [CrossRef]
625. Bittner DO, Mayrhofer T, Budoff M, et al. Prognostic value of coronary CTA in stable chest pain: CAD-RADS, CAC, and cardiovascular events in PROMISE. *JACC Cardiovasc Imaging*. 2020;13(7):1534-1545. [CrossRef]
626. Szilveszter B, Vattay B, Bossoussou M, et al. CAD-RADS may underestimate coronary plaque progression as detected by serial CT angiography. *Eur Heart J Cardiovasc Imaging*. 2022;23(11):1530-1539. [CrossRef]
627. Conte E, Mushtaq S, Pontone G, et al. Plaque quantification by coronary computed tomography angiography using intravascular ultrasound as a reference standard: A comparison between standard and last generation computed tomography scanners. *Eur Heart J Cardiovasc Imaging*. 2020;21(2):191-201. [CrossRef]
628. Conte E, Annoni A, Pontone G, et al. Evaluation of coronary plaque characteristics with coronary computed tomography angiography in patients with non-obstructive coronary artery disease: A long-term follow-up study. *Eur Heart J Cardiovasc Imaging*. 2017;18(10):1170-1178. [CrossRef]
629. Mangiacapra F, Bressi E, Sticchi A, Morisco C, Barbato E. Fractional flow reserve (FFR) as a guide to treat coronary artery disease. *Expert Rev Cardiovasc Ther*. 2018;16(7):465-477. [CrossRef]
630. Patel MR, Nørgaard BL, Fairbairn TA, et al. 1-Year impact on medical practice and clinical outcomes of FFR_{CT}: The ADVANCE registry. *JACC Cardiovasc Imaging*. 2020;13(1 Pt 1):97-105. [CrossRef]
631. Nørgaard BL, Gaur S, Fairbairn TA, et al. Prognostic value of coronary computed tomography angiographic derived fractional flow reserve: A systematic review and meta-analysis. *Heart*. 2022;108(3):194-202. [CrossRef]
632. Pontone G, Andreini D, Guaricci AI, et al. Incremental diagnostic value of stress computed tomography myocardial perfusion with whole-heart coverage CT scanner in intermediate- to high-risk symptomatic patients suspected of coronary artery disease. *JACC Cardiovasc Imaging*. 2019;12(2):338-349. [CrossRef]
633. Pontone G, Baggiano A, Andreini D, et al. Dynamic stress computed tomography perfusion with a whole-heart coverage scanner in addition to coronary computed tomography angiography and fractional flow reserve computed tomography derived. *JACC Cardiovasc Imaging*. 2019;12(12):2460-2471. [CrossRef]
634. Baggiano A, Fusini L, Del Torto A, et al. Sequential strategy including FFR_{CT} plus stress-CTP impacts on management of patients with stable chest pain: The stress-CTP RIPCORD study. *J Clin Med*. 2020;9(7):2147. [CrossRef]
635. Baggiano A, Italiano G, Guglielmo M, et al. Changing paradigms in the diagnosis of ischemic heart disease by multimodality imaging. *J Clin Med*. 2022;11(3):477. [CrossRef]
636. Schuijff JD, Poldermans D, Shaw LJ, et al. Diagnostic and prognostic value of non-invasive imaging in known or suspected coronary artery disease. *Eur J Nucl Med Mol Imaging*. 2006;33(1):93-104. [CrossRef]
637. Cantoni V, Green R, Acampa W, et al. Diagnostic performance of myocardial perfusion imaging with conventional and CZT single-photon emission computed tomography in detecting coronary artery disease: A meta-analysis. *J Nucl Cardiol*. 2021;28(2):698-715. [CrossRef]
638. Piccini JP, Horton JR, Shaw LK, et al. Single-photon emission computed tomography myocardial perfusion defects are associated with an increased risk of all-cause death, cardiovascular death, and sudden cardiac death. *Circ Cardiovasc Imaging*. 2008;1(3):180-188. [CrossRef]
639. Otaki Y, Betancur J, Sharir T, et al. 5-Year prognostic value of quantitative versus visual MPI in subtle perfusion defects: Results from REFINE SPECT. *JACC Cardiovasc Imaging*. 2020;13(3):774-785. [CrossRef]
640. Nammas W, Maaniitty T, Knuuti J, Saraste A. Cardiac perfusion by positron emission tomography. *Clin Physiol Funct Imaging*. 2021;41(5):385-400. [CrossRef]
641. Kajander S, Joutsiniemi E, Saraste M, et al. Cardiac positron emission tomography/computed tomography imaging accurately detects anatomically and functionally significant coronary artery disease. *Circulation*. 2010;122(6):603-613. [CrossRef]
642. Di Carli MF, Dorbala S, Meserve J, El Fakhri G, Sitek A, Moore SC. Clinical myocardial perfusion PET/CT. *J Nucl Med*. 2007;48(5):783-793. [CrossRef]
643. Danad I, Uusitalo V, Kero T, et al. Quantitative assessment of myocardial perfusion in the detection of significant coronary artery disease: Cutoff values and diagnostic accuracy of quantitative [(15)O]H₂O PET imaging. *J Am Coll Cardiol*. 2014;64(14):1464-1475. [CrossRef]
644. Herzog BA, Husmann L, Valenta I, et al. Long-term prognostic value of 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. *J Am Coll Cardiol*. 2009;54(2):150-156. [CrossRef]
645. Schinkel AF, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernating myocardium: Diagnosis and patient outcomes. *Curr Probl Cardiol*. 2007;32(7):375-410. [CrossRef]
646. Schinkel AF, Poldermans D, Elhendy A, Bax JJ. Assessment of myocardial viability in patients with heart failure. *J Nucl Med*. 2007;48(7):1135-1146. [CrossRef]
647. van Dijk R, van Assen M, Vliegenhart R, de Bock GH, van der Harst P, Oudkerk M. Diagnostic performance of semi-quantitative and quantitative stress CMR perfusion analysis: A meta-analysis. *J Cardiovasc Magn Reson*. 2017;19(1):92. [CrossRef]
648. Nagel E, Greenwood JP, McCann GP, et al. Magnetic resonance perfusion or fractional flow reserve in coronary disease. *N Engl J Med*. 2019;380(25):2418-2428. [CrossRef]
649. Greenwood JP, Maredia N, Younger JF, Brown JM, Nixon J, Everett CC, et al. Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): A prospective trial. *Lancet*. 2012;379(9814):453-460. [CrossRef]
650. Pontone G, Guaricci AI, Palmer SC, et al. Diagnostic performance of non-invasive imaging for stable coronary artery disease: A meta-analysis. *Int J Cardiol*. 2020;300:276-281. [CrossRef]
651. Kwong RY, Ge Y, Steel K, et al. Cardiac magnetic resonance stress perfusion imaging for evaluation of patients with chest pain. *J Am Coll Cardiol*. 2019;74(14):1741-1755. [CrossRef]
652. Ambale-Venkatesh B, Lima JA. Cardiac MRI: A central prognostic tool in myocardial fibrosis. *Nat Rev Cardiol*. 2015;12(1):18-29. [CrossRef]
653. Messroghli DR, Moon JC, Ferreira VM, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). *J Cardiovasc Magn Reson*. 2017;19(1):75. [CrossRef]
654. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. *N Engl J Med*. 2000;343(20):1445-1453. [CrossRef]

655. Jimenez Juan L, Crean AM, Wintersperger BJ. Late gadolinium enhancement imaging in assessment of myocardial viability: Techniques and clinical applications. *Radiol Clin North Am*. 2015;53(2):397-411. [CrossRef]
656. Romero J, Xue X, Gonzalez W, Garcia MJ. CMR imaging assessing viability in patients with chronic ventricular dysfunction due to coronary artery disease: A meta-analysis of prospective trials. *JACC Cardiovasc Imaging*. 2012;5(5):494-508. [CrossRef]
657. Schelbert EB, Piehler KM, Zareba KM, et al. Myocardial fibrosis quantified by extracellular volume is associated with subsequent hospitalization for heart failure, death, or both across the spectrum of ejection fraction and heart failure stage. *J Am Heart Assoc*. 2015;4(12):e002613. [CrossRef]
658. Weinsaft JW, Kim RJ, Ross M, et al. Contrast-enhanced anatomic imaging as compared to contrast-enhanced tissue characterization for detection of left ventricular thrombus. *JACC Cardiovasc Imaging*. 2009;2(8):969-979. [CrossRef]
659. Chaosuwannakit N, Makarawate P. Left ventricular thrombi: Insights from cardiac magnetic resonance imaging. *Tomography*. 2021;7(2):180-188. [CrossRef]
660. Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: A position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. *Eur J Heart Fail*. 2010;12(8):767-778. [CrossRef]
661. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. *Eur Heart J*. 2018;39(34):3165-3241. [CrossRef]
662. Davis MB, Arany Z, McNamara DM, Goland S, Elkayam U. Peripartum cardiomyopathy: JACC state-of-the-art review. *J Am Coll Cardiol*. 2020;75(2):207-221. [CrossRef]
663. Arany Z. Peripartum cardiomyopathy. *NEngl J Med*. 2024;390(2):154-164. [CrossRef]
664. Kolte D, Khera S, Aronow WS, et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. *J Am Heart Assoc*. 2014;3(3):e001056. [CrossRef]
665. Mielniczuk LM, Williams K, Davis DR, et al. Frequency of peripartum cardiomyopathy. *Am J Cardiol*. 2006;97(12):1765-1768. [CrossRef]
666. Arany Z, Elkayam U. Peripartum cardiomyopathy. *Circulation*. 2016;133(14):1397-1409. [CrossRef]
667. Bello NA, Arany Z. Molecular mechanisms of peripartum cardiomyopathy: A vascular/hormonal hypothesis. *Trends Cardiovasc Med*. 2015;25(6):499-504. [CrossRef]
668. Ruys TP, Roos-Hesselink JW, Hall R, et al. Heart failure in pregnant women with cardiac disease: Data from the ROPAC. *Heart*. 2014;100(3):231-238. [CrossRef]
669. Gentry MB, Dias JK, Luis A, Patel R, Thornton J, Reed GL. African-American women have a higher risk for developing peripartum cardiomyopathy. *J Am Coll Cardiol*. 2010;55(7):654-659. [CrossRef]
670. Bello N, Rendon ISH, Arany Z. The relationship between pre-eclampsia and peripartum cardiomyopathy: A systematic review and meta-analysis. *J Am Coll Cardiol*. 2013;62(18):1715-1723. [CrossRef]
671. Brar SS, Khan SS, Sandhu GK, et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. *Am J Cardiol*. 2007;100(2):302-304. [CrossRef]
672. Pearl W. Familial occurrence of peripartum cardiomyopathy. *Am Heart J*. 1995;129(2):421-422. [CrossRef]
673. Baruteau AE, Leurent G, Schleich JM, Gervais R, Daubert JC, Mabo P. Can peripartum cardiomyopathy be familial? *Int J Cardiol*. 2009;137(2):183-185. [CrossRef]
674. van Spaendonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. *Circulation*. 2010;121(20):2169-2175. [CrossRef]
675. Haghikia A, Podewski E, Libhaber E, et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. *Basic Res Cardiol*. 2013;108(4):366. [CrossRef]
676. Horne BD, Rasmusson KD, Alharethi R, et al. Genome-wide significance and replication of the chromosome 12p11.22 locus near the PTHLH gene for peripartum cardiomyopathy. *Circ Cardiovasc Genet*. 2011;4(4):359-366. [CrossRef]
677. Ware JS, Li J, Mazaika E, et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. *N Engl J Med*. 2016;374(3):233-241. [CrossRef]
678. Haggerty CM, Damrauer SM, Levin MG, et al. Genomics-first evaluation of heart disease associated with titin-truncating variants. *Circulation*. 2019;140(1):42-54. [CrossRef]
679. Elkayam U, Akhter MW, Singh H, Khan S, Bitar F, Hameed A, Shotan A. Pregnancy-associated cardiomyopathy: Clinical characteristics and a comparison between early and late presentation. *Circulation*. 2005;111(16):2050-2055. [CrossRef]
680. Sliwa K, Petrie MC, van der Meer P, et al. Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: An ESC EORP registry. *Eur Heart J*. 2020;41(39):3787-3797. [CrossRef]
681. Fett JD. Earlier detection can help avoid many serious complications of peripartum cardiomyopathy. *Future Cardiol*. 2013;9(6):809-816. [CrossRef]
682. Goland S, Modi K, Bitar F, et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. *J Card Fail*. 2009;15(8):645-650. [CrossRef]
683. Bauersachs J, König T, van der Meer P, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: A position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. *Eur J Heart Fail*. 2019;21(7):827-843. [CrossRef]
684. Honigberg MC, Elkayam U, Rajagopalan N, et al. Electrocardiographic findings in peripartum cardiomyopathy. *Clin Cardiol*. 2019;42(5):524-529. [CrossRef]
685. Tanous D, Siu SC, Mason J, et al. B-type natriuretic peptide in pregnant women with heart disease. *J Am Coll Cardiol*. 2010;56(15):1247-1253. [CrossRef]
686. Harper MA, Meyer RE, Berg CJ. Peripartum cardiomyopathy: Population-based birth prevalence and 7-year mortality. *Obstet Gynecol*. 2012;120(5):1013-1019. [CrossRef]
687. Cooper LT, Mather PJ, Alexis JD, et al. Myocardial recovery in peripartum cardiomyopathy: Prospective comparison with recent onset cardiomyopathy in men and nonperipartum women. *J Card Fail*. 2012;18(1):28-33. [CrossRef]
688. McNamara DM, Elkayam U, Alharethi R, et al. Clinical outcomes for peripartum cardiomyopathy in North America: Results of the IPAC study (investigations of pregnancy-associated cardiomyopathy). *J Am Coll Cardiol*. 2015;66(8):905-914. [CrossRef]
689. Koutrolou-Sotiropoulou P, Lima FV, Stergiopoulos K. Quality of life in survivors of peripartum cardiomyopathy. *Am J Cardiol*. 2016;118(2):258-263. [CrossRef]
690. Banayan J, Rana S, Mueller A, et al. Cardiogenic shock in pregnancy: Analysis from the national inpatient sample. *Hypertens Pregnancy*. 2017;36(2):117-123. [CrossRef]
691. Goland S, Bitar F, Modi K, et al. Evaluation of the clinical relevance of baseline left ventricular ejection fraction as a predictor of recovery or persistence of severe dysfunction in women in the United States with peripartum cardiomyopathy. *J Card Fail*. 2011;17(5):426-430. [CrossRef]
692. Sliwa K, Mebazaa A, Hilfiker-Kleiner D, et al. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. *Eur J Heart Fail*. 2017;19(9):1131-1141. [CrossRef]
693. Felker GM, Jaeger CJ, Klodas E, et al. Myocarditis and long-term survival in peripartum cardiomyopathy. *Am Heart J*. 2000;140(5):785-791. [CrossRef]
694. Biteker M, Ilhan E, Biteker G, Duman D, Bozkurt B. Delayed recovery in peripartum cardiomyopathy: An indication for long-term follow-up and sustained therapy. *Eur J Heart Fail*. 2012;14(8):895-901. [CrossRef]

695. Xu H, Zhao L, Fu H, et al. Prognostic value of cardiac MRI late gadolinium enhancement in patients with peripartum cardiomyopathy: A retrospective study. *Curr Probl Cardiol.* 2023;48(4):101587. [\[CrossRef\]](#)
696. Malhamé I, Dayan N, Moura CS, Samuel M, Vinet E, Pilote L. Peripartum cardiomyopathy with co-incident preeclampsia: A cohort study of clinical risk factors and outcomes among commercially insured women. *Pregnancy Hypertens.* 2019;17:82-88. [\[CrossRef\]](#)
697. Hu CL, Li YB, Zou YG, et al. Troponin T measurement can predict persistent left ventricular dysfunction in peripartum cardiomyopathy. *Heart.* 2007;93(4):488-490. [\[CrossRef\]](#)
698. Forster O, Hilfiker-Kleiner D, Ansari AA, et al. Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. *Eur J Heart Fail.* 2008;10(9):861-868. [\[CrossRef\]](#)
699. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2022;79(17):1757-1780. [\[CrossRef\]](#)
700. Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States: Diagnosis, prognosis, and management. *J Am Coll Cardiol.* 2011;58(7):659-670. [\[CrossRef\]](#)
701. Bozkurt B, Colvin M, Cook J, et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: A scientific statement from the American Heart Association. *Circulation.* 2016;134(23):e579-e646. [\[CrossRef\]](#)
702. Bauersachs J, Arrigo M, Hilfiker-Kleiner D, et al. Current management of patients with severe acute peripartum cardiomyopathy: Practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. *Eur J Heart Fail.* 2016;18(9):1096-1105. [\[CrossRef\]](#)
703. Zimmerman H, Bose R, Smith R, Copeland JG. Treatment of peripartum cardiomyopathy with mechanical assist devices and cardiac transplantation. *Ann Thorac Surg.* 2010;89(4):1211-1217. [\[CrossRef\]](#)
704. Elkayam U. Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy. *J Am Coll Cardiol.* 2014;64(15):1629-1636. [\[CrossRef\]](#)
705. Gümüş E, Özen H. Glycogen storage diseases: An update. *World J Gastroenterol.* 2023;29(25):3932-3963. [\[CrossRef\]](#)
706. Nair V, Belanger EC, Veinot JP. Lysosomal storage disorders affecting the heart: a review. *Cardiovasc Pathol.* 2019;39:12-24. [\[CrossRef\]](#)
707. Hannah WB, Derks TGJ, Drumm ML, Grünert SC, Kishnani PS, Vissing J. Glycogen storage diseases. *Nat Rev Dis Primers.* 2023;9(1):46. [\[CrossRef\]](#)
708. Cameron JM, Levandovskiy V, MacKay N, et al. Identification of a novel mutation in GYS1 (muscle-specific glycogen synthase) resulting in sudden cardiac death, that is diagnosable from skin fibroblasts. *Mol Genet Metab.* 2009;98(4):378-382. [\[CrossRef\]](#)
709. Kollberg G, Tulinius M, Gilljam T, et al. Cardiomyopathy and exercise intolerance in muscle glycogen storage disease O. *N Engl J Med.* 2007;357(15):1507-1514. [\[CrossRef\]](#)
710. van der Ploeg AT, Reuser AJ. Pompe's disease. *Lancet.* 2008;372(9646):1342-1353. [\[CrossRef\]](#)
711. Toscano A, Rodolico C, Musumeci O. Multisystem late onset Pompe disease (LOPD): an update on clinical aspects. *Ann Transl Med.* 2019;7(13):284. [\[CrossRef\]](#)
712. Fayssol A, Nardi O, Annane D, Orlikowski D. Right ventricular function in late-onset Pompe disease. *J Clin Monit Comput.* 2014;28(4):419-421. [\[CrossRef\]](#)
713. Nemes A, Soliman OI, Geleijnse ML, et al. Increased aortic stiffness in glycogenosis type 2 (Pompe's disease). *Int J Cardiol.* 2007;120(1):138-141. [\[CrossRef\]](#)
714. Lotan D, Salazar-Mendiguchía J, Mogensen J, et al; Cooperating Investigators. Clinical Profile of Cardiac Involvement in Danon Disease: A Multicenter European Registry. *Circ Genom Precis Med.* 2020;13:e003117.
715. Rigolli M, Kahn AM, Brambatti M, Contijoch FJ, Adler ED. Cardiac Magnetic Resonance Imaging in Danon Disease Cardiomyopathy. *JACC Cardiovasc Imaging.* 2021;14(2):514-516. [\[CrossRef\]](#)
716. Dara BS, Rusconi PG, Fishman JE. Danon disease: characteristic late gadolinium enhancement pattern on cardiac magnetic resonance imaging. *Cardiol Young.* 2011;21(6):707-709. [\[CrossRef\]](#)
717. Conte F, Sam JE, Lefeber DJ, Passier R. Metabolic Cardiomyopathies and Cardiac Defects in Inherited Disorders of Carbohydrate Metabolism: A Systematic Review. *Int J Mol Sci.* 2023;24(10):8632. [\[CrossRef\]](#)
718. Porto AG, Brun F, Severini GM, et al. Clinical Spectrum of PRKAG2 Syndrome. *Circ Arrhythm Electrophysiol.* 2016;9(1):e003121. [\[CrossRef\]](#)
719. Pöyhönen P, Hiippala A, Ollila L, et al. Cardiovascular magnetic resonance findings in patients with PRKAG2 gene mutations. *J Cardiovasc Magn Reson.* 2015;17:89. [\[CrossRef\]](#)
720. Kishnani PS, Austin SL, Arn P, et al.; ACMG. Glycogen storage disease type III diagnosis and management guidelines. *Genet Med.* 2010;12(7):446-463. Erratum in: *Genet Med.* 2010;12(9):566. [\[CrossRef\]](#)
721. Austin SL, Proia AD, Spencer-Manzong MJ, Butany J, Wechsler SB, Kishnani PS. Cardiac Pathology in Glycogen Storage Disease Type III. *JIMD Rep.* 2012;6:65-72. [\[CrossRef\]](#)
722. Szymańska E, Szymańska S, Truszkowska G, et al. Variable clinical presentation of glycogen storage disease type IV: from severe hepatosplenomegaly to cardiac insufficiency. Some discrepancies in genetic and biochemical abnormalities. *Arch Med Sci.* 2018;14(1):237-247. [\[CrossRef\]](#)
723. Aksu T, Colak A, Tufekcioglu O. Cardiac Involvement in Glycogen Storage Disease Type IV: Two Cases and the Two Ends of a Spectrum. *Case Rep Med.* 2012;2012:764286. [\[CrossRef\]](#)
724. Hedberg-Oldfors C, Glamuzina E, Ruygrok P, et al. Cardiomyopathy as presenting sign of glycogenin-1 deficiency-report of three cases and review of the literature. *J Inherit Metab Dis.* 2017;40(1):139-149. [\[CrossRef\]](#)
725. Mancheño N, Braza-Boïls A, Muelas N, Ejarque-Doménech I, Martínez-Dolz L, Zorio E. Cardiac phenotype in glycogen storage disease type XV: a rare cardiomyopathy to bear in mind. *Rev Esp Cardiol (Engl Ed).* 2021;74(1):99-101. English, Spanish. [\[CrossRef\]](#)
726. Altassan R, Radenkovic S, Edmondson AC, et al. International consensus guidelines for phosphoglucomutase 1 deficiency (PGM1-CDG): Diagnosis, follow-up, and management. *J Inherit Metab Dis.* 2021;44(1):148-163. [\[CrossRef\]](#)
727. Campuzano V, Montermini L, Moltò MD, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. *Science.* 1996;271(5254):1423-1427. [\[CrossRef\]](#)
728. Monda E, Lioncino M, Rubino M, et al. Diagnosis and Management of Cardiovascular Involvement in Friedreich Ataxia. *Heart Fail Clin.* 2022;18(1):31-37. [\[CrossRef\]](#)
729. Pousset F, Legrand L, Monin ML, et al. A 22-Year Follow-up Study of Long-term Cardiac Outcome and Predictors of Survival in Friedreich Ataxia. *JAMA Neurol.* 2015;72(11):1334-1341. [\[CrossRef\]](#)
730. Vyas PM, Tomamichel WJ, Pride PM, et al. A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse model. *Hum Mol Genet.* 2012;21(6):1230-1247. [\[CrossRef\]](#)
731. Michael S, Petrocine SV, Qian J, et al. Iron and iron-responsive proteins in the cardiomyopathy of Friedreich's ataxia. *Cerebellum.* 2006;5(4):257-267. [\[CrossRef\]](#)
732. Regner SR, Lagedrost SJ, Plappert T, et al. Analysis of echocardiograms in a large heterogeneous cohort of patients with friedreich ataxia. *Am J Cardiol.* 2012;109(3):401-405. [\[CrossRef\]](#)
733. St John Sutton M, Ky B, Regner SR, et al. Longitudinal strain in Friedreich Ataxia: a potential marker for early left ventricular dysfunction. *Echocardiography.* 2014;31(1):50-57. [\[CrossRef\]](#)
734. Liu D, Hu K, Nordbeck P, Ertl G, Störk S, Weidemann F. Longitudinal strain bull's eye plot patterns in patients with cardiomyopathy and concentric left ventricular hypertrophy. *Eur J Med Res.* 2016;21(1):21. [\[CrossRef\]](#)

735. Milano EG, Harries IB, Bucciarelli-Ducci C. Young adult with Friedreich ataxia. *Heart*. 2019;105(10):797-806. [\[CrossRef\]](#)
736. Weidemann F, Liu D, Hu K, et al. The cardiomyopathy in Friedreich's ataxia - New biomarker for staging cardiac involvement. *Int J Cardiol*. 2015;194:50-57. [\[CrossRef\]](#)
737. Pudil R, Danzig V, Veselý J, et al.; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). *Cor Vasa*. 2023;65(2):350-434. [\[CrossRef\]](#)
738. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared Risk Factors in Cardiovascular Disease and Cancer. *Circulation*. 2016;133(11):1104-1114. [\[CrossRef\]](#)
739. Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR. Early Breast Cancer Therapy and Cardiovascular Injury. *J Am Coll Cardiol*. 2007;50(15):1435-1441. [\[CrossRef\]](#)
740. Saleh Y, Abdelkarim O, Herzallah K, Abela GS. Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment. *Heart Fail Rev*. 2021;26(5):1159-1173. [\[CrossRef\]](#)
741. Mohan N, Jiang J, Dokmanovic M, Wu WJ. Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers. *Antib Ther*. 2018;1(1):13-17. [\[CrossRef\]](#)
742. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. *Nat Rev Cardiol*. 2015;12(9):547-558. [\[CrossRef\]](#)
743. Belzile-Dugas E, Eisenberg MJ. Radiation-Induced Cardiovascular Disease: Review of an Underrecognized Pathology. *J Am Heart Assoc*. 2021;10(18):e021686. Erratum in: *J Am Heart Assoc*. 2023;12(10):e027687. [\[CrossRef\]](#)
744. Plana JC, Thavandiranathan P, Bucciarelli-Ducci C, Lancellotti P. Multi-Modality Imaging in the Assessment of Cardiovascular Toxicity in the Cancer Patient. *JACC Cardiovasc Imaging*. 2018;11(8):1173-1186. Erratum in: *JACC Cardiovasc Imaging*. 2019;12(1):224. [\[CrossRef\]](#)
745. Thavandiranathan P, Grant AD, Negishi T, Plana JC, Popović ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. *J Am Coll Cardiol*. 2013;61(1):77-84. [\[CrossRef\]](#)
746. Hoffmann R, Barletta G, von Bardeleben S, et al. Analysis of left ventricular volumes and function: a multicenter comparison of cardiac magnetic resonance imaging, cine ventriculography, and unenhanced and contrast-enhanced two-dimensional and three-dimensional echocardiography. *J Am Soc Echocardiogr*. 2014;27(3):292-301. [\[CrossRef\]](#)
747. Porter TR, Mulvagh SL, Abdelmoneim SS, et al. Clinical Applications of Ultrasonic Enhancing Agents in Echocardiography: 2018 American Society of Echocardiography Guidelines Update. *J Am Soc Echocardiogr*. 2018;31(3):241-274. [\[CrossRef\]](#)
748. Makavos G, Ikonomidis I, Palios J, et al. Cardiac imaging in cardiotoxicity: a focus on clinical practice. *Heart Fail Rev*. 2021;26(5):1175-1187. [\[CrossRef\]](#)
749. Thavandiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. *J Am Coll Cardiol*. 2014;63(25 Pt A):2751-2768. [\[CrossRef\]](#)
750. Oikonomou EK, Kokkinidis DG, Kampaktis PN, et al. Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis. *JAMA Cardiol*. 2019;4(10):1007-1018. [\[CrossRef\]](#)
751. Yu C, Pathan F, Tan TC, Negishi K. The Utility of Advanced Cardiovascular Imaging in Cancer Patients-When, Why, How, and the Latest Developments. *Front Cardiovasc Med*. 2021;8:728215. [\[CrossRef\]](#)
752. Vallabhaneni S, Zhang KW, Alvarez-Cardona JA, et al. Role of cardiovascular magnetic resonance in early detection and treatment of cardiac dysfunction in oncology patients. *Int J Cardiovasc Imaging*. 2021;37(10):3003-3017. [\[CrossRef\]](#)
753. Löffler AI, Salerno M. Cardiac MRI for the evaluation of oncologic cardiotoxicity. *J Nucl Cardiol*. 2018;25(6):2148-2158. [\[CrossRef\]](#)
754. Medina KM, Abdel-Gadir A, Ganga K, et al. Use of rapid cardiac magnetic resonance imaging to guide chelation therapy in patients with transfusion-dependent thalassaemia in India: UMIMI study. *Eur Heart J Qual Care Clin Outcomes*. 2022;8(3):289-297. [\[CrossRef\]](#)
755. Dhir V, Yan AT, Nisenbaum R, Sloninko J, et al. Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study. *Int J Cardiovasc Imaging*. 2019;35(11):2085-2093. [\[CrossRef\]](#)
756. Cannizzaro MT, Inserra MC, Passaniti G, et al. Role of advanced cardiovascular imaging in chemotherapy-induced cardiotoxicity. *Heliyon*. 2023;9(4):e15226. [\[CrossRef\]](#)
757. Dote K, Sato H, Tateishi H, Uchida T, Ishihara M. Myocardial stunning due to simultaneous multivessel coronary spasms: a review of 5 cases. *J Cardiol*. 1991;21(2):203-214. Japanese.
758. Pavin D, Le Breton H, Daubert C. Human stress cardiomyopathy mimicking acute myocardial syndrome. *Heart*. 1997;78(5):509-511. [\[CrossRef\]](#)
759. Sharkey SW, Lesser JR, Maron MS, Maron BJ. Why not just call it tako-tsubo cardiomyopathy: a discussion of nomenclature. *J Am Coll Cardiol*. 2011;57(13):1496-1497. [\[CrossRef\]](#)
760. Sharkey SW, Maron BJ. Epidemiology and clinical profile of Takotsubo cardiomyopathy. *Circ J*. 2014;78(9):2119-2128. [\[CrossRef\]](#)
761. Akashi YJ, Nef HM, Lyon AR. Epidemiology and pathophysiology of Takotsubo syndrome. *Nat Rev Cardiol*. 2015;12(7):387-397. [\[CrossRef\]](#)
762. Komamura K, Fukui M, Iwasaku T, Hirotsu S, Masuyama T. Takotsubo cardiomyopathy: Pathophysiology, diagnosis and treatment. *World J Cardiol*. 2014;6(7):602-609. [\[CrossRef\]](#)
763. Lyon AR, Citro R, Schneider B, Morel O, Ghadri JR, Templin C, et al. Pathophysiology of Takotsubo Syndrome: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2021;77(7):902-921. [\[CrossRef\]](#)
764. Parodi G, Del Pace S, Carrabba N, Salvadori C, Memisha G, Simonetti I, et al. Incidence, clinical findings, and outcome of women with left ventricular apical ballooning syndrome. *Am J Cardiol*. 2007;99(2):182-185. [\[CrossRef\]](#)
765. Templin C, Ghadri JR, Diekmann J, et al. Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. *N Engl J Med*. 2015;373(10):929-938. [\[CrossRef\]](#)
766. Shah RM, Shah M, Shah S, Li A, Jauhar S. Takotsubo Syndrome and COVID-19: Associations and Implications. *Curr Probl Cardiol*. 2021;46(3):100763. [\[CrossRef\]](#)
767. Wittstein IS, Thiemann DR, Lima JA, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. *N Engl J Med*. 2005;352(6):539-548. [\[CrossRef\]](#)
768. Abraham J, Mudd JO, Kapur NK, Klein K, Champion HC, Wittstein IS. Stress cardiomyopathy after intravenous administration of catecholamines and beta-receptor agonists. *J Am Coll Cardiol*. 2009;53(15):1320-1325. Erratum in: *J Am Coll Cardiol*. 2009;53(19):1828. [\[CrossRef\]](#)
769. Galiuto L, De Caterina AR, Porfida A, et al. Reversible coronary microvascular dysfunction: a common pathogenetic mechanism in Apical Ballooning or Tako-Tsubo Syndrome. *Eur Heart J*. 2010;31(11):1319-1327. [\[CrossRef\]](#)
770. Prasad A, Lerman A, Rihal CS. Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. *Am Heart J*. 2008;155(3):408-417. [\[CrossRef\]](#)
771. Sanchez-Jimenez EF. Initial clinical presentation of Takotsubo cardiomyopathy with-a focus on electrocardiographic changes: A literature review of cases. *World J Cardiol*. 2013;5(7):228-241. [\[CrossRef\]](#)
772. Ogura R, Hiasa Y, Takahashi T, et al. Specific findings of the standard 12-lead ECG in patients with 'Takotsubo' cardiomyopathy: comparison with the findings of acute anterior myocardial infarction. *Circ J*. 2003;67(8):687-690. [\[CrossRef\]](#)
773. Cheema AN, Yanagawa B, Verma S, Bagai A, Liu S. Myocardial infarction with nonobstructive coronary artery disease (MINOCA): a review of pathophysiology and management. *Curr Opin Cardiol*. 2021;36(5):589-596. [\[CrossRef\]](#)

774. Abe Y, Kondo M, Matsuoka R, Araki M, Dohyama K, Tanio H. Assessment of clinical features in transient left ventricular apical ballooning. *J Am Coll Cardiol*. 2003;41(5):737–742. [CrossRef]
775. Ghadri JR, Wittstein IS, Prasad A, et al. International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. *Eur Heart J*. 2018;39(22):2032–2046. [CrossRef]
776. Ghadri JR, Kato K, Cammann VL, et al. Long-Term Prognosis of Patients with Takotsubo Syndrome. *J Am Coll Cardiol*. 2018;72(8):874–882. [CrossRef]
777. Citro R, Lyon AR, Meimoun P, et al. Standard and advanced echocardiography in takotsubo (stress) cardiomyopathy: clinical and prognostic implications. *J Am Soc Echocardiogr*. 2015;28(1):57–74. [CrossRef]
778. Eitel I, von Knobelsdorff-Brenkenhoff F, Bernhardt P, et al. Clinical characteristics and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyopathy. *JAMA*. 2011;306(3):277–286. [CrossRef]
779. Elesber AA, Prasad A, Lennon RJ, Wright RS, Lerman A, Rihal CS. Four-year recurrence rate and prognosis of the apical ballooning syndrome. *J Am Coll Cardiol*. 2007;50(5):448–452. [CrossRef]
780. Nef HM, Möllmann H, Kostin S, et al. Tako-Tsubo cardiomyopathy: intraindividual structural analysis in the acute phase and after functional recovery. *Eur Heart J*. 2007;28(20):2456–2464. [CrossRef]
781. Padayachee L. Levosimendan: the inotrope of choice in cardiogenic shock secondary to takotsubo cardiomyopathy? *Heart Lung Circ*. 2007;16 Suppl 3:S65–S70. [CrossRef]
782. Madias JE. Takotsubo Cardiomyopathy: Current Treatment. *J Clin Med*. 2021;10(15):3440. [CrossRef]
783. Maron BJ, Towbin JA, Thiene G, et al.; American Heart Association; Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; Council on Epidemiology and Prevention. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. *Circulation*. 2006;113(14):1807–1816. [CrossRef]
784. Petersen SE, Jensen B, Aung N, et al. Excessive Trabeculation of the Left Ventricle: JACC: Cardiovascular Imaging Expert Panel Paper. *JACC Cardiovasc Imaging*. 2023;16(3):408–425. [CrossRef]
785. Gati S, Chandra N, Bennett RL, et al. Increased left ventricular trabeculation in highly trained athletes: do we need more stringent criteria for the diagnosis of left ventricular non-compaction in athletes? *Heart*. 2013;99(6):401–408. Erratum in: *Heart*. 2013;99(7):506. Wilson, Matthew [corrected to Wilson, Mathew]. [CrossRef]
786. Gati S, Papadakis M, Papamichael ND, et al. Reversible de novo left ventricular trabeculations in pregnant women: implications for the diagnosis of left ventricular noncompaction in low-risk populations. *Circulation*. 2014;130(6):475–483. [CrossRef]
787. Finsterer J, Stöllberger C, Towbin JA. Left ventricular noncompaction cardiomyopathy: cardiac, neuromuscular, and genetic factors. *Nat Rev Cardiol*. 2017;14(4):224–237. [CrossRef]
788. Arbustini E, Favalli V, Narula N, Serio A, Grasso M. Left Ventricular Noncompaction: A Distinct Genetic Cardiomyopathy? *J Am Coll Cardiol*. 2016;68(9):949–966. Erratum in: *J Am Coll Cardiol*. 2016;68(16):1821. [CrossRef]
789. Ross SB, Jones K, Blanch B, et al. A systematic review and meta-analysis of the prevalence of left ventricular non-compaction in adults. *Eur Heart J*. 2020;41(14):1428–1436. [CrossRef]
790. Chin TK, Perloff JK, Williams RG, Jue K, Mohrmann R. Isolated noncompaction of left ventricular myocardium. A study of eight cases. *Circulation*. 1990;82(2):507–513. [CrossRef]
791. Jenni R, Oechslin E, Schneider J, Attenhofer Jost C, Kaufmann PA. Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-compaction: a step towards classification as a distinct cardiomyopathy. *Heart*. 2001 Dec;86(6):666–671. [CrossRef]
792. Adabifirouzjaei F, Igata S, DeMaria AN. Hypertrabeculation; a phenotype with Heterogeneous etiology. *Prog Cardiovasc Dis*. 2021;68:60–69. [CrossRef]
793. Stöllberger C, Finsterer J. Left ventricular hypertrabeculation/noncompaction. *J Am Soc Echocardiogr*. 2004;17(1):91–100. [CrossRef]
794. Petersen SE, Selvanayagam JB, Wiesmann F, et al. Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. *J Am Coll Cardiol*. 2005;46(1):101–105. [CrossRef]
795. Kawel N, Nacif M, Arai AE, et al. Trabeculated (noncompacted) and compact myocardium in adults: the multi-ethnic study of atherosclerosis. *Circ Cardiovasc Imaging*. 2012;5(3):35–366. [CrossRef]
796. Jacquier A, Thuny F, Jop B, et al. Measurement of trabeculated left ventricular mass using cardiac magnetic resonance imaging in the diagnosis of left ventricular non-compaction. *Eur Heart J*. 2010;31(9):1098–1104. [CrossRef]
797. Casas G, Rodríguez-Palomares JF, Ferreira-González I. Left ventricular noncompaction: a disease or a phenotypic trait? *Rev Esp Cardiol (Engl Ed)*. 2022;75(12):1059–1069. English, Spanish. [CrossRef]
798. Stacey RB, Andersen MM, St Clair M, Hundley WG, Thohan V. Comparison of systolic and diastolic criteria for isolated LV noncompaction in CMR. *JACC Cardiovasc Imaging*. 2013;6(9):931–940. [CrossRef]
799. Grothoff M, Pachowsky M, Hoffmann J, et al. Value of cardiovascular MR in diagnosing left ventricular non-compaction cardiomyopathy and in discriminating between other cardiomyopathies. *Eur Radiol*. 2012;22(12):2699–2709. [CrossRef]
800. Captur G, Muthurangu V, Cook C, et al. Quantification of left ventricular trabeculae using fractal analysis. *J Cardiovasc Magn Reson*. 2013;15(1):36. [CrossRef]
801. Captur G, Zemrak F, Muthurangu V, et al. Fractal Analysis of Myocardial Trabeculations in 2547 Study Participants: Multi-Ethnic Study of Atherosclerosis. *Radiology*. 2015;277(3):707–715. [CrossRef]
802. Melendez-Ramirez G, Castillo-Castellon F, Espinola-Zavaleta N, Meave A, Kimura-Hayama ET. Left ventricular noncompaction: a proposal of new diagnostic criteria by multidetector computed tomography. *J Cardiovasc Comput Tomogr*. 2012;6(5):346–354. [CrossRef]
803. Sidhu MS, Uthamalingam S, Ahmed W, et al. Defining left ventricular noncompaction using cardiac computed tomography. *J Thorac Imaging*. 2014;29(1):60–66. [CrossRef]
804. Fuchs TA, Erhart L, Ghadri JR, et al. Diagnostic criteria for left ventricular non-compaction in cardiac computed tomography. *PLoS One*. 2020;15(7):e0235751. [CrossRef]
805. Zemrak F, Ahlman MA, Captur G, et al. The relationship of left ventricular trabeculation to ventricular function and structure over a 9.5-year follow-up: the MESA study. *J Am Coll Cardiol*. 2014;64(19):1971–1980. [CrossRef]
806. Weir-McCall JR, Yeap PM, Papagiorcopulo C, et al. Left Ventricular Noncompaction: Anatomical Phenotype or Distinct Cardiomyopathy? *J Am Coll Cardiol*. 2016;68(20):2157–2165. [CrossRef]
807. Kohli SK, Pantazis AA, Shah JS, et al. Diagnosis of left-ventricular non-compaction in patients with left-ventricular systolic dysfunction: time for a reappraisal of diagnostic criteria? *Eur Heart J*. 2008;29(1):89–95. [CrossRef]
808. Agmon Y, Connolly HM, Olson LJ, Khandheria BK, Seward JB. Noncompaction of the ventricular myocardium. *J Am Soc Echocardiogr*. 1999;12(10):859–863. [CrossRef]
809. Aras D, Tufekcioglu O, Ergun K, et al. Clinical features of isolated ventricular noncompaction in adults long-term clinical course, echocardiographic properties, and predictors of left ventricular failure. *J Card Fail*. 2006;12(9):726–733. [CrossRef]
810. Stöllberger C, Finsterer J, Blazek G. Left ventricular hypertrabeculation/noncompaction and association with additional cardiac abnormalities and neuromuscular disorders. *Am J Cardiol*. 2002;90(8):899–902. [CrossRef]
811. D'Silva A, Sharma S. Differentiating athlete's heart from left ventricular non-compaction car- diomyopathy. In: Pelliccia A, Heidbuchel H, Corrado D, Borjesson M, Sharma S, eds. *The ESC Textbook of Sports Cardiology*. Oxford: Oxford University Press; 2019:210–217. [CrossRef]

812. Caselli S, Ferreira D, Kanawati E, et al. Prominent left ventricular trabeculations in competitive athletes: A proposal for risk stratification and management. *Int J Cardiol.* 2016;223:590-595. [CrossRef]
813. Gati S, Merghani A, Sharma S. Increased left ventricular trabeculation does not necessarily equate to left ventricular noncompaction in athletes. *JAMA Intern Med.* 2015;175(3):461-462. [CrossRef]
814. Gati S, Sharma S. CardioPulse: the dilemmas in diagnosing left ventricular non-compaction in athletes. *Eur Heart J.* 2015;36(15):891-893.
815. Harmon KG, Asif IM, Maleszewski JJ, et al. Incidence, Cause, and Comparative Frequency of Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A Decade in Review. *Circulation.* 2015;132(1):10-19. [CrossRef]
816. Maron BJ, Zipes DP, Kovacs RJ; American Heart Association Electrocardiography and Arrhythmias Committee of Council on Clinical Cardiology, Council on Cardiovascular Disease in Young, Council on Cardiovascular and Stroke Nursing, Council on Functional Genomics and Translational Biology, and American College of Cardiology. Eligibility and Disqualification Recommendations for Competitive Athletes with Cardiovascular Abnormalities: Preamble, Principles, and General Considerations: A Scientific Statement From the American Heart Association and American College of Cardiology. *Circulation.* 2015;132(22):e256-e261. [CrossRef]
817. Woodbridge SP, Aung N, Paiva JM, et al. Physical activity and left ventricular trabeculation in the UK Biobank community-based cohort study. *Heart.* 2019;105(13):990-998. [CrossRef]
818. Reimold SC. Reversible left ventricular trabeculations in pregnancy: is this sufficient to make the diagnosis of left ventricular noncompaction? *Circulation.* 2014;130(6):453-454. [CrossRef]
819. Caliskan K, Soliman OI, ten Cate FJ, eds. *Noncompaction Cardiomyopathy.* 1st ed. SpringerLink; 2019. [CrossRef]
820. Chebib FT, Hogan MC, El-Zoghby ZM, et al. Autosomal Dominant Polycystic Kidney Patients May Be Predisposed to Various Cardiomyopathies. *Kidney Int Rep.* 2017;2(5):913-923. [CrossRef]
821. Bell PE, Hossack KF, Gabow PA, Durr JA, Johnson AM, Schrier RW. Hypertension in autosomal dominant polycystic kidney disease. *Kidney Int.* 1988;34(5):683-690. [CrossRef]
822. Piga A, Longo F, Musallam KM, et al. Left ventricular noncompaction in patients with β -thalassemia: uncovering a previously unrecognized abnormality. *Am J Hematol.* 2012;87(12):1079-1083. [CrossRef]
823. Gati S, Papadakis M, Van Niekerk N, Reed M, Yeghen T, Sharma S. Increased left ventricular trabeculation in individuals with sickle cell anaemia: physiology or pathology? *Int J Cardiol.* 2013;168(2):1658-1660. [CrossRef]
824. Gladwin MT, Sachdev V. Cardiovascular abnormalities in sickle cell disease. *J Am Coll Cardiol.* 2012;59(13):1123-1133. [CrossRef]
825. Navarrete G, Pozo E, Díez-Villanueva P, et al. Spongy Ischemic Myocardium: Dealing With Morphological Criteria of Noncompaction Cardiomyopathy. *Circ Heart Fail.* 2017;10(1):e003718. [CrossRef]
826. Eurlings LW, Pinto YM, Dennert RM, Bekkers SC. Reversible isolated left ventricular non-compaction? *Int J Cardiol.* 2009;136(2):e35-e36. [CrossRef]
827. Stähli BE, Gebhard C, Biaggi P, et al. Left ventricular non-compaction: prevalence in congenital heart disease. *Int J Cardiol.* 2013;167(6):2477-2481. [CrossRef]
828. Zemrak F, Raisi-Estabragh Z, Khanji MY, et al. Left Ventricular Hypertrabeculation Is Not Associated With Cardiovascular Morbidity or Mortality: Insights From the Eurocmr Registry. *Front Cardiovasc Med.* 2020;7:158. [CrossRef]
829. Amzulescu MS, Rousseau MF, Ahn SA, et al. Prognostic Impact of Hypertrabeculation and Noncompaction Phenotype in Dilated Cardiomyopathy: A CMR Study. *JACC Cardiovasc Imaging.* 2015;8(8):934-946. [CrossRef]
830. Ivanov A, Dabiesingh DS, Bhumireddy GP, et al. Prevalence and Prognostic Significance of Left Ventricular Noncompaction in Patients Referred for Cardiac Magnetic Resonance Imaging. *Circ Cardiovasc Imaging.* 2017;10(9):e006174. [CrossRef]
831. Grigoratos C, Barison A, Ivanov A, et al. Meta-Analysis of the Prognostic Role of Late Gadolinium Enhancement and Global Systolic Impairment in Left Ventricular Noncompaction. *JACC Cardiovasc Imaging.* 2019;12(11 Pt 1):2141-2151. [CrossRef]
832. Cooper LT Jr. Myocarditis. *N Engl J Med.* 2009;360(15):1526-1538. [CrossRef]
833. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet.* 2015;386(9995):743-800.
834. McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J.* 2021;42(36):3599-3726. Erratum in: *Eur Heart J.* 2021;42(48):4901.
835. Leuschner F, Katus HA, Kaya Z. Autoimmune myocarditis: past, present and future. *J Autoimmun.* 2009;33(3-4):282-289. [CrossRef]
836. Cunningham MW. Turning point in myocarditis. *Circ Res.* 2009;105(5):403-405. [CrossRef]
837. Liguori C, Farina D, Vaccher F, Ferrandino G, Bellini D, Carbone I. Myocarditis: imaging up to date. *Radiol Med.* 2020;125(11):1124-1134. [CrossRef]
838. Metzger TC, Anderson MS. Myocarditis: a defect in central immune tolerance? *J Clin Invest.* 2011;121(4):1251-1253. [CrossRef]
839. Li HS, Ligons DL, Rose NR. Genetic complexity of autoimmune myocarditis. *Autoimmun Rev.* 2008;7(3):168-173. [CrossRef]
840. Caforio AL, Daliento L, Angelini A, et al. Autoimmune myocarditis and dilated cardiomyopathy: focus on cardiac autoantibodies. *Lupus.* 2005;14(9):652-655. [CrossRef]
841. Gabibov AG, Ponomarenko NA, Tretyak EB, Paltsev MA, Suchkov SV. Catalytic autoantibodies in clinical autoimmunity and modern medicine. *Autoimmun Rev.* 2006;5(5):324-330. [CrossRef]
842. Kühl U, Pauschinger M, Noutsias M, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. *Circulation.* 2005;111(7):887-893. [CrossRef]
843. Jain D, Halushka MK. Cardiac pathology of systemic lupus erythematosus. *J Clin Pathol.* 2009;62(7):584-592. [CrossRef]
844. Mavrogeni S, Spargias K, Markussis V, et al. Myocardial inflammation in autoimmune diseases: investigation by cardiovascular magnetic resonance and endomyocardial biopsy. *Inflamm Allergy Drug Targets.* 2009;8(5):390-397. [CrossRef]
845. Mavrogeni S, Bratis K, Kolovou G. Pathophysiology of Q waves in II, III, aVF in systemic lupus erythematosus. Evaluation using cardiovascular magnetic resonance imaging. *Lupus.* 2012;21(8):821-829. [CrossRef]
846. Toong C, Puranik R, Adelstein S. Use of cardiac MR imaging to evaluate the presence of myocarditis in autoimmune myositis: three cases. *Rheumatol Int.* 2012;32(3):779-782. [CrossRef]
847. Nieminen MS, Heikkilä J, Karjalainen J. Echocardiography in acute infectious myocarditis: relation to clinical and electrocardiographic findings. *Am J Cardiol.* 1984;53(9):1331-1337. [CrossRef]
848. Pinamonti B, Alberti E, Cigalotto A, et al. Echocardiographic findings in myocarditis. *Am J Cardiol.* 1988;62(4):285-291. [CrossRef]
849. Mendes LA, Dec GW, Picard MH, Palacios IF, Newell J, Davidoff R. Right ventricular dysfunction: an independent predictor of adverse outcome in patients with myocarditis. *Am Heart J.* 1994;128(2):301-307. [CrossRef]
850. Hiramitsu S, Morimoto S, Kato S, et al. Transient ventricular wall thickening in acute myocarditis: a serial echocardiographic and histopathologic study. *Jpn Circ J.* 2001;65(10):863-866. [CrossRef]
851. Adsett M, West MJ, Galbraith A, Duhig E, Lange A, Palka P. Eosinophilic heart: marked left ventricular wall thickening and myocardial dysfunction improving with corticosteroid therapy. *Echocardiography.* 2003;20(4):369-374. [CrossRef]
852. Kondo M, Takahashi M, Shimono Y, Fujiwara H, Miyazaki S, Matsuda T. Reversible asymmetric septal hypertrophy in acute myocarditis. Serial findings of two-dimensional echocardiogram and thallium-201 scintigram. *Jpn Circ J.* 1985;49(6):589-593. [CrossRef]
853. Wilansky S, Pollick C. Acute myocarditis presenting as asymmetric septal hypertrophy. *Can J Cardiol.* 1989;5(2):75-76.
854. Lieback E, Hardouin I, Meyer R, Bellach J, Hetzer R. Clinical value of echocardiographic tissue characterization in the diagnosis of myocarditis. *Eur Heart J.* 1996;17(1):135-142. [CrossRef]
855. Ueda T, Mizushige K, Aoyama T, Tokuda M, Kiyomoto H, Matsuo H. Echocardiographic observation of acute myocarditis with systemic lupus erythematosus. *Jpn Circ J.* 2000;64(2):144-146. [CrossRef]

856. Omi W, Nagai H, Takata S, Yuasa T, Sakagami S, Kobayashi K. Ultrasonic tissue characterization in acute myocarditis: a case report. *Circ J*. 2002;66(4):416-418. [CrossRef]
857. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis—natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. *N Engl J Med*. 1997;336(26):1860-1866. [CrossRef]
858. Okura Y, Dec GW, Hare JM, et al. A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. *J Am Coll Cardiol*. 2003;41(2):322-329. [CrossRef]
859. Xu J, Brooks EG. Giant Cell Myocarditis: A Brief Review. *Arch Pathol Lab Med*. 2016;140(12):1429-1434. [CrossRef]
860. Liu X, Jin F, Guo T, Wang Q, Fang L, Chen W. Relative basal myocardial weakness: differentiating dermatomyositis and polymyositis with cardiac involvement from viral myocarditis using speckle-tracking echocardiography and quantification of myocardial work. *Quant Imaging Med Surg*. 2022;12(7):3762-3777. [CrossRef]
861. Leitman M, Vered Z, Tyomkin V, et al. Speckle tracking imaging in inflammatory heart diseases. *Int J Cardiovasc Imaging*. 2018;34(5):787-792. [CrossRef]
862. Jacobs JC, Rosen JM, Szer IS. Lyme myocarditis diagnosed by gallium scan. *J Pediatr*. 1984;105(6):950-952. [CrossRef]
863. Matsuura H, Ishikita T, Yamamoto S, et al. Gallium-67 myocardial imaging for the detection of myocarditis in the acute phase of Kawasaki disease (mucocutaneous lymph node syndrome): the usefulness of single photon emission computed tomography. *Br Heart J*. 1987;58(4):385-392. [CrossRef]
864. Khaw BA, Fallon JT, Beller GA, Haber E. Specificity of localization of myosin-specific antibody fragments in experimental myocardial infarction. Histologic, histochemical, autoradiographic and scintigraphic studies. *Circulation*. 1979;60(7):1527-1531. [CrossRef]
865. Kishimoto C, Hung GL, Ishibashi M, et al. Natural evolution of cardiac function, cardiac pathology and antimyosin scan in a murine myocarditis model. *J Am Coll Cardiol*. 1991;17(3):821-827. [CrossRef]
866. Friedrich MG, Sechtem U, Schulz-Menger J, et al.; International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. *J Am Coll Cardiol*. 2009;53(17):1475-1487. [CrossRef]
867. De Cobelli F, Pieroni M, Esposito A, et al. Delayed gadolinium-enhanced cardiac magnetic resonance in patients with chronic myocarditis presenting with heart failure or recurrent arrhythmias. *J Am Coll Cardiol*. 2006;47(8):1649-1654. [CrossRef]
868. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. *Eur Heart J*. 2005;26(15):1461-1474. [CrossRef]
869. Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. *Circulation*. 2004;109(10):1250-1258. [CrossRef]
870. Francone M, Chimenti C, Galea N, et al. CMR sensitivity varies with clinical presentation and extent of cell necrosis in biopsy-proven acute myocarditis. *JACC Cardiovasc Imaging*. 2014;7(3):254-263. [CrossRef]
871. Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. *J Am Coll Cardiol*. 2018;72(24):3158-3176. [CrossRef]
872. Li L, Bainbridge MN, Tan Y, Willerson JT, Marian AJ. A Potential oligogenic etiology of hypertrophic cardiomyopathy: A classic single-gene disorder. *Circ Res*. 2017;120(7):1084-1090. [CrossRef]
873. Ingles J, Goldstein J, Thaxton C, et al. Evaluating the clinical validity of hypertrophic cardiomyopathy genes. *Circ Genom Precis Med*. 2019;12(2):e002460. [CrossRef]
874. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015;17(5):405-424. [CrossRef]
875. Ireland CG, Ho CY. Genetic testing in hypertrophic cardiomyopathy. *Am J Cardiol*. 2024;212S:S4-S13. [CrossRef]
876. Lorenzini M, Norrish G, Field E, et al. Penetrance of hypertrophic cardiomyopathy in sarcomere protein mutation carriers. *J Am Coll Cardiol*. 2020;76(5):550-559. [CrossRef]
877. Marian AJ. Molecular genetic basis of hypertrophic cardiomyopathy. *Circ Res*. 2021;128(10):1533-1553. [CrossRef]
878. Kontorovich AR. Approaches to genetic screening in cardiomyopathies: Practical Guidance for clinicians. *JACC Heart Fail*. 2023;11(2):133-142. [CrossRef]
879. Hoss S, Habib M, Silver J, et al. Genetic testing for diagnosis of hypertrophic cardiomyopathy mimics: Yield and clinical significance. *Circ Genom Precis Med*. 2020;13(2):e002748. [CrossRef]
880. Vardarli I, Weber M, Rischpler C, Führer D, Herrmann K, Weidemann F. Fabry cardiomyopathy: Current treatment and future options. *J Clin Med*. 2021;10(14):3026. [CrossRef]
881. Türkmen H, Uysal F, Bostan ÖM. A rare and fatal cause of hypertrophic cardiomyopathy: Danon disease. *Cardiol Young*. 2023;33(8):1448-1450. [CrossRef]
882. Wilde AAM, Semsarian C, Márquez MF, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert consensus statement on the state of genetic testing for cardiac diseases. *Europace*. 2022;24(8):1307-1367. [CrossRef]
883. Mathew J, Zahavich L, Lafreniere-Roula M, et al. Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy. *Clin Genet*. 2018;93(2):310-319. [CrossRef]
884. Ho CY, Day SM, Ashley EA, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). *Circulation*. 2018;138(14):1387-1398. [CrossRef]
885. Haas J, Frese KS, Peil B, et al. Atlas of the clinical genetics of human dilated cardiomyopathy. *Eur Heart J*. 2015;36(18):1123-1135a.
886. Escobar-Lopez L, Ochoa JP, Mirelis JG, et al. Association of genetic variants with outcomes in patients with nonischemic dilated cardiomyopathy. *J Am Coll Cardiol*. 2021;78(17):1682-1699. [CrossRef]
887. Kayvanpour E, Sedaghat-Hamedani F, Amr A, et al. Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on more than 8000 individuals. *Clin Res Cardiol*. 2017;106(2):127-139. [CrossRef]
888. Ader F, De Groote P, Réant P, et al. FLNC pathogenic variants in patients with cardiomyopathies: Prevalence and genotype-phenotype correlations. *Clin Genet*. 2019;96(4):317-329. [CrossRef]
889. Walsh R, Thomson KL, Ware JS, et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. *Genet Med*. 2017;19(2):192-203. [CrossRef]
890. Ortiz-Genga MF, Cuenca S, Dal Ferro M, et al. Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies. *J Am Coll Cardiol*. 2016;68(22):2440-2451. [CrossRef]
891. Towbin JA, McKenna WJ, Abrams DJ, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. *Heart Rhythm*. 2019;16(11):e301-e372. [CrossRef]
892. Richard P, Ader F, Roux M, et al. Targeted panel sequencing in adult patients with left ventricular non-compaction reveals a large genetic heterogeneity. *Clin Genet*. 2019;95(3):356-367. [CrossRef]
893. van Waning JI, Caliskan K, Hoedemaekers YM, et al. Genetics, clinical features, and long-term outcome of noncompaction cardiomyopathy. *J Am Coll Cardiol*. 2018;71(7):711-722. [CrossRef]
894. Ross SB, Semsarian C. Clinical and genetic complexities of left ventricular noncompaction: Preventing overdiagnosis in a disease we do not understand. *JAMA Cardiol*. 2018;3(11):1033-1034. [CrossRef]
895. Emdin M, Aimo A, Rapezzi C, et al. Treatment of cardiac transthyretin amyloidosis: An update. *Eur Heart J*. 2019;40(45):3699-3706. [CrossRef]